<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for preventing and treating incontinence‐associated dermatitis in adults - Beeckman, D - 2016 | Cochrane Library</title> <meta content="Interventions for preventing and treating incontinence‐associated dermatitis in adults - Beeckman, D - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011627.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for preventing and treating incontinence‐associated dermatitis in adults - Beeckman, D - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011627.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011627.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for preventing and treating incontinence‐associated dermatitis in adults" name="citation_title"/> <meta content="Dimitri Beeckman" name="citation_author"/> <meta content="Ghent University" name="citation_author_institution"/> <meta content="Dimitri.Beeckman@UGent.be" name="citation_author_email"/> <meta content="Nele Van Damme" name="citation_author"/> <meta content="Ghent University" name="citation_author_institution"/> <meta content="Lisette Schoonhoven" name="citation_author"/> <meta content="University of Southampton" name="citation_author_institution"/> <meta content="Aurélie Van Lancker" name="citation_author"/> <meta content="Ghent University" name="citation_author_institution"/> <meta content="Jan Kottner" name="citation_author"/> <meta content="Charité‐Universitätsmedizin Berlin" name="citation_author_institution"/> <meta content="Hilde Beele" name="citation_author"/> <meta content="Ghent University, Ghent University Hospital" name="citation_author_institution"/> <meta content="Mikel Gray" name="citation_author"/> <meta content="University of Virginia" name="citation_author_institution"/> <meta content="Sue Woodward" name="citation_author"/> <meta content="King's College London" name="citation_author_institution"/> <meta content="Mandy Fader" name="citation_author"/> <meta content="University of Southampton" name="citation_author_institution"/> <meta content="Karen Van den Bussche" name="citation_author"/> <meta content="Ghent University" name="citation_author_institution"/> <meta content="Ann Van Hecke" name="citation_author"/> <meta content="Ghent University" name="citation_author_institution"/> <meta content="Dorien De Meyer" name="citation_author"/> <meta content="Ghent University" name="citation_author_institution"/> <meta content="Sofie Verhaeghe" name="citation_author"/> <meta content="Ghent University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD011627.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/11/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011627.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011627.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011627.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Topical; Amitriptyline [administration &amp; dosage]; Dermatitis [etiology, prevention &amp; control, *therapy]; Dermatologic Agents [*administration &amp; dosage]; Fecal Incontinence [*complications]; Petrolatum [administration &amp; dosage]; Randomized Controlled Trials as Topic; Skin Care [methods]; Skin Cream [administration &amp; dosage]; Soaps [administration &amp; dosage]; Urinary Incontinence [*complications]; Zinc Oxide [administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011627.pub2&amp;doi=10.1002/14651858.CD011627.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="xcg9958b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011627\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011627\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","hr","fa","de"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011627.pub2",title:"Interventions for preventing and treating incontinence\\u2010associated dermatitis in adults",firstPublishedDate:"Nov 14, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Incontinence Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011627.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011627.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011627.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011627.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011627.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011627.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011627.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011627.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011627.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011627.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>17946 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011627.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#CD011627-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#CD011627-sec-0147"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#CD011627-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#CD011627-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#CD011627-sec-0041"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#CD011627-sec-0042"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#CD011627-sec-0063"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#CD011627-sec-0139"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/appendices#CD011627-sec-0152"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/table_n/CD011627StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/table_n/CD011627StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for preventing and treating incontinence‐associated dermatitis in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#CD011627-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Dimitri Beeckman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#CD011627-cr-0003">Nele Van Damme</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#CD011627-cr-0004">Lisette Schoonhoven</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#CD011627-cr-0005">Aurélie Van Lancker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#CD011627-cr-0006">Jan Kottner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#CD011627-cr-0007">Hilde Beele</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#CD011627-cr-0008">Mikel Gray</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#CD011627-cr-0009">Sue Woodward</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#CD011627-cr-0010">Mandy Fader</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#CD011627-cr-0011">Karen Van den Bussche</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#CD011627-cr-0012">Ann Van Hecke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#CD011627-cr-0013">Dorien De Meyer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information#CD011627-cr-0014">Sofie Verhaeghe</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information/en#CD011627-sec-0164">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 November 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011627.pub2">https://doi.org/10.1002/14651858.CD011627.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011627-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011627-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011627-abs-0011">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011627-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011627-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011627-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011627-abs-0001" lang="en"> <section id="CD011627-sec-0001"> <h3 class="title" id="CD011627-sec-0001">Background</h3> <p>Incontinence‐associated dermatitis (IAD) is one of the most common skin problems in adults who are incontinent for urine, stool, or both. In practice, products and procedures are the same for both prevention and treatment of IAD. </p> </section> <section id="CD011627-sec-0002"> <h3 class="title" id="CD011627-sec-0002">Objectives</h3> <p>The objective of this review was to assess the effectiveness of various products and procedures to prevent<br/> and treat incontinence‐associated dermatitis in adults. </p> </section> <section id="CD011627-sec-0003"> <h3 class="title" id="CD011627-sec-0003">Search methods</h3> <p>We searched the Cochrane Incontinence Group Specialised Trials Register, which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In‐Process, MEDLINE Epub Ahead of Print, CINAHL, ClinicalTrials.gov, WHO ICTRP and handsearching of journals and conference proceedings (searched 28 September 2016). Additionally we searched other electronic databases: CENTRAL(2015, Issue 4), MEDLINE (January 1946 to May Week 3 2015), MEDLINE In‐Process (inception to 26 May 2015), CINAHL(December 1981 to 28 May 2015), Web of Science (WoS; inception to 28 May 2015) and handsearched conference proceedings (to June 2015) and the reference lists of relevant articles, and contacted authors and experts in the field. </p> </section> <section id="CD011627-sec-0004"> <h3 class="title" id="CD011627-sec-0004">Selection criteria</h3> <p>We selected randomised controlled trials (RCTs) and quasi‐RCTs, performed in any healthcare setting, with included participants over 18 years of age, with or without IAD. We included trials comparing the (cost) effectiveness of topical skin care products such as skin cleansers, moisturisers, and skin protectants of different compositions and skin care procedures aiming to prevent and treat IAD. </p> </section> <section id="CD011627-sec-0005"> <h3 class="title" id="CD011627-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened titles, abstracts and full‐texts, extracted data, and assessed the risk of bias of the included trials. </p> </section> <section id="CD011627-sec-0006"> <h3 class="title" id="CD011627-sec-0006">Main results</h3> <p>We included 13 trials with 1316 participants in a qualitative synthesis. Participants were incontinent for urine, stool, or both, and were residents in a nursing home or were hospitalised. </p> <p>Eleven trials had a small sample size and short follow‐up periods. .The overall risk of bias in the included studies was high. The data were not suitable for meta‐analysis due to heterogeneity in participant population, skin care products, skin care procedures, outcomes, and measurement tools. </p> <p>Nine trials compared different topical skin care products, including a combination of products. Two trials tested a structured skin care procedure. One trial compared topical skin care products alongside frequencies of application. One trial compared frequencies of application of topical skin care products. </p> <p>We found evidence in two trials, being of low and moderate quality, that soap and water performed poorly in the prevention and treatment of IAD (primary outcomes of this review). The first trial indicated that the use of a skin cleanser might be more effective than the use of soap and water (risk ratio (RR) 0.39, 95% confidence interval (CI) 0.17 to 0.87; low quality evidence). The second trial indicated that a structured skin care procedure, being a washcloth with cleansing, moisturising, and protecting properties, might be more effective than soap and water (RR 0.31, 95% CI 0.12 to 0.79; moderate quality evidence). Findings from the other trials, all being of low to very low quality, suggest that applying a leave‐on product (moisturiser, skin protectant, or a combination) might be more effective than not applying a leave‐on product. No trial reported on the third primary outcome 'number of participants not satisfied with treatment' or on adverse effects. </p> </section> <section id="CD011627-sec-0007"> <h3 class="title" id="CD011627-sec-0007">Authors' conclusions</h3> <p>Little evidence, of very low to moderate quality, exists on the effects of interventions for preventing and treating IAD in adults. Soap and water performed poorly in the prevention and treatment of IAD. Application of leave‐on products (moisturisers, skin protectants, or a combination) and avoiding soap seems to be more effective than withholding these products. The performance of leave‐on products depends on the combination of ingredients, the overall formulation and the usage (e.g. amount applied). High quality confirmatory trials using standardised, and comparable prevention and treatment regimens in different settings/regions are required. Furthermore, to increase the comparability of trial results, we recommend the development of a core outcome set, including validated measurement tools. The evidence in this review is current up to 28 September 2016. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011627-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011627-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011627-abs-0012">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011627-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011627-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011627-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011627-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011627-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011627-abs-0003" lang="en"> <h3>Interventions for preventing and treating incontinence‐associated dermatitis in adults</h3> <p><b>Background</b> </p> <p>Incontinence‐associated dermatitis (IAD) is an inflammation of the skin due to contact with urine or stool. IAD occurs in people with involuntary loss of urine or stool (incontinence). The main symptom of IAD is skin redness. In addition, bullae, skin lesions, and skin infection may occur. IAD affects one to five in ten incontinent adults and is a risk factor for pressure‐related skin problems. To prevent and treat IAD, skin cleansing and skin care products are recommended. Many skin care products and procedures are available. The skin care products can be divided into cleansers, moisturisers, and protectants which may be combined (for example, a cleanser/moisturiser). In practice, products and procedures are the same for both prevention and treatment. </p> <p><b>Review question</b> </p> <p>This review clarified the effect of various skin care products and procedures to prevent and treat IAD. </p> <p><b>Study characteristics</b> </p> <p>We included randomised controlled trials which compared skin care products, procedures, methods for using skin care products and frequencies of using a skin care product. The participants had to be over 18 years of age. </p> <p><b>Key results</b> </p> <p>We found thirteen, mostly small, trials, involving 1316 participants. All participants were incontinent for urine, stool, or both and lived in nursing homes or were hospitalised. The trials tested skin care products, procedures, and frequencies of using a skin care product. </p> <p>Two trials showed that soap and water performed poorly in the prevention and treatment of IAD. A skin cleanser or a washcloth with cleansing, moisturising and protecting properties may be more effective than soap and water. The findings from the other trials suggest that using a skin care product is more effective than withholding a skin care product. We found no evidence that one skin care product performed better than another. The trials did not report on adverse effects. </p> <p><b>Quality of evidence</b> </p> <p>The quality of the evidence was low. Eleven trials had small numbers of participants and were of short duration. The overall risk of bias was high. </p> <p><b>Authors conclusions</b> </p> <p>The trials included in this review tested skin care products, procedures and frequencies of using a skin care product. Very limited evidence exists on the effects of interventions for preventing and treating IAD in adults. Larger, long‐term and well performed trials are required. Furthermore, we recommend the development of a list of outcomes which are important for patients and will guide researchers in their study. This list should include well developed tools to measure the items in order to obtain accurate results. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>The review authors searched for studies that had been published up to 28 September 2016. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011627-sec-0147" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011627-sec-0147"></div> <h3 class="title" id="CD011627-sec-0148">Implications for practice</h3> <section id="CD011627-sec-0148"> <p>There is little evidence, of very low to moderate quality, on the effectiveness of interventions for preventing and treating incontinence‐associated dermatitis (IAD) in adults. Consequently, it's not clear whether any leave‐on product (moisturiser, skin protectant, single or combined) performs better than another. Using a leave‐on product and avoiding soap is better than using nothing. The performance of leave‐on products depends on the combination of ingredients, the overall formulation and the usage (e.g. amount applied). </p> </section> <h3 class="title" id="CD011627-sec-0149">Implications for research</h3> <section id="CD011627-sec-0149"> <p>The current literature on interventions for preventing and treating IAD in adults consists of a few small trials of low to, at most, moderate quality. None of the trials identified were comparable in terms of trial set‐up. In addition, the functioning of the tested leave‐on products was unclear (moisturising, skin protecting, or both). Furthermore, we found no data on several participant‐important outcomes. </p> <p>Future trials should try to overcome the methodological weaknesses identified through this review. First of all, we recommend the use of sample sizes large enough to reflect possible differences in effectiveness of interventions. A priori sample size calculation is mandatory. In addition, we recommend more efforts to blind the outcome assessment and to use valid methods for randomisation of participants and allocation concealment. </p> <p>Researchers must report the results of their trials accurately and according to <a href="./references#CD011627-bbs2-0048" title="SchulzKF , AltmanDG , MoherD , the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. www.consort‐statement.org/consort‐2010 (accessed 8 February 2016). ">CONSORT 2010</a>. We identified a lack of reporting of standard deviations, absolute frequencies, and levels of significance (P values). These data are essential to adequately interpret the research results and to compare outcomes across trials (e.g. in a meta‐analysis). Another consideration is the time of follow‐up. For interventions aimed at preventing IAD, we recommend a follow‐up period of at least six weeks, based on the time to develop IAD which is between one and 42 days (<a href="./references#CD011627-bbs2-0047" title="BlissD , SavikK , ThorsonM , EhmanS , LebakK , BeilmanG . Incontinence‐associated dermatitis in critically ill adults: time to development, severity, and risk factors. Journal of Wound, Ostomy, and Continence Nursing2011;38(4):433‐45. ">Bliss 2011</a>). For interventions aimed at treating IAD, we recommend a follow‐up period of at least three weeks, based on the time to IAD‐healing which is between one and 19 days (<a href="./references#CD011627-bbs2-0047" title="BlissD , SavikK , ThorsonM , EhmanS , LebakK , BeilmanG . Incontinence‐associated dermatitis in critically ill adults: time to development, severity, and risk factors. Journal of Wound, Ostomy, and Continence Nursing2011;38(4):433‐45. ">Bliss 2011</a>). High quality confirmatory studies will enhance valuable conclusions about the effectiveness of products and procedures to prevent and treat IAD. We further recommend using standardised and comparable prevention and/or treatment regimens in different settings/regions. </p> <p>While performing our review, we determined that the function of the skin care products (moisturising versus skin protecting) was not always clear. To enhance the interpretation and comprehensibility of the results of our Cochrane Review, we classified all products not being a skin cleanser as leave‐on products. The latter group consisted of moisturisers and skin protectants, either as a separate product or combined into one product. To enhance correct product selection and comparability in practice and research, we highly recommend the use of a standardised language and terminology in the description of skin care products. </p> <p>There is a need for uniform, relevant, and participant‐important outcomes. Patients should be involved in the selection of these outcomes, to enhance the contribution of trial results in informed decision‐making. Based on our experience with this Cochrane Review, we recommend the development of a core set of outcomes. This may improve the comparability of outcomes across studies. More comparability is important to be able to pool results. Recently the IAD International Research Group has launched a project which aims to develop a core outcome set of well‐defined IAD‐related outcomes for clinical IAD research. This outcome set will also include validated tools for outcome measurement (<a href="./references#CD011627-bbs2-0046" title="BeeckmanD , KottnerJ , IAD International Research Group. Developing a core outcome set for incontinence‐associated dermatitis (IAD) research. www.comet‐initiative.org/studies/details/383 (accessed 8 February 2016). ">Beeckman 2015a</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011627-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011627-sec-0029"></div> <div class="table" id="CD011627-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Any topical skin care product versus another topical skin care product</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Any topical skin care product versus another topical skin care product</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with incontinence<br/> <b>Setting:</b> hospitals and nursing homes<br/> <b>Intervention:</b> any topical skin care product<br/> <b>Comparison:</b> another topical skin care product </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with skin care product B</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with skin care product A</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (residual, i.e. not healed)</b> </p> <p>(1) No‐rinse skin cleanser and skin cream (A) versus soap and water and lotion (B)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.36<br/> (0.08 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on one small study.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1.000<br/> (25 to 517) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (residual, i.e. not healed)</b> </p> <p>(2) Desitin (A) versus Calmoseptine (B)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.16</p> <p>(1.00 to 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>142</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Basd on one study and sponsored by industry.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>783 per 1.000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>908 per 1.000<br/> (783 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (new)</b> </p> <p>(1) Skin cleanser (A) versus soap and water (B)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.39<br/> (0.17 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on one small study and sponsored by industry.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>469 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1.000<br/> (80 to 408) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (new)</b> </p> <p>(2) Sudocrem (A) versus zinc oxide cream (B)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (0.20 to 5.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on one small study.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1.000<br/> (36 to 944) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (new)</b> </p> <p>(3) No‐rinse skin cleanser/moisturiser and a film‐forming skin product (A) versus cleansing/moisturising/skin protecting washcloth (B) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/> (0.35 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>64<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on one small study. Corresponding author was member of the company who delivered the study products. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>226 per 1.000<br/> (95 to 532) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants not satisfied with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to IAD</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to skin care product or procedure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse reaction due to the skin care product or procedure, e.g. skin irritation, rash, itching, allergic</b> <br/> <b>reaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incremental cost‐effectiveness</b> </p> <p>Zinc oxide oil (A) versus film‐forming skin product (B)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One small study reported data on this outcome. The results on cost‐effectiveness were on average in favour of the film‐forming skin product. Due to limited reporting of statistical data, it is unclear whether these differences in cost‐effectiveness are real. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IAD</b> : incontinence‐associated dermatitis; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011627-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with incontinence<br/> <b>Setting:</b> nursing homes<br/> <b>Intervention:</b> any skin care procedure (method or frequency of application)<br/> <b>Comparison:</b> any unstructured skin care procedure </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any unstructured skin care procedure (B)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any skin care procedure (method or frequency of application) (A)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (residual, i.e. not healed)</b> </p> <p>(1) Washcloth with cleansing, moisturising, and protecting properties (A) versus water and pH neutral soap (B) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.31<br/> (0.12 to 0.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on one study.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>259 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1.000<br/> (31 to 204) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with IAD (new)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants not satisfied with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to IAD</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to skin care product or procedure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse reaction due to the skin care product or procedure, e.g. skin irritation, rash, itching, allergic</b> <br/> <b>reaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incremental cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IAD</b> : incontinence‐associated dermatitis; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011627-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Any method of application of a topical skin care product versus another method of application of the topical skin care product</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Any method of application of a topical skin care product versus another</b> <br/> <b>method of application of the topical skin care product</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with incontinence<br/> <b>Setting:</b> <br/> <b>Intervention:</b> any method of application of a topical skin care product<br/> <b>Comparison:</b> any other method of application of the topical skin care product </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any unstructured skin care procedure (B)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any skin care procedure (method or frequency of application) (A)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (residual, i.e. not healed)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with IAD (new)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants not satisfied with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to IAD</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to skin care product or procedure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse reaction due to the skin care product or procedure, e.g. skin irritation, rash, itching, allergic<br/> reaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incremental cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IAD</b> : incontinence‐associated dermatitis; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011627-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Any frequency of application of a topical skin care product versus another frequency of application of the topical skin care product</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Any frequency of application of a topical skin care product versus another<br/> frequency of application of the topical skin care product</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with incontinence<br/> <b>Setting:</b> <br/> <b>Intervention:</b> any frequency of application of a topical skin care product<br/> <b>Comparison:</b> any other frequency of application of the topical skin care product </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any unstructured skin care procedure (B)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any skin care procedure (method or frequency of application) (A)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (residual, i.e. not healed)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with IAD (new)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants not satisfied with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to IAD</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to skin care product or procedure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse reaction due to the skin care product or procedure, e.g. skin irritation, rash, itching, allergic<br/> reaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incremental cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IAD</b> : incontinence‐associated dermatitis; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011627-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011627-sec-0030"></div> <section id="CD011627-sec-0031"> <h3 class="title" id="CD011627-sec-0031">Description of the condition</h3> <p>Incontinence is defined as the complaint of any involuntary loss of urine (urine incontinence) or faecal material (faecal incontinence) or both (double incontinence) (<a href="./references#CD011627-bbs2-0058" title="International Scientific Committee. Recommendations of the International Scientific Committee. Incontinence: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. Fourth International Consultation on Incontinence; 2008 July 5‐9; Paris. Plymouth, UK: Health Publication Ltd, 2009. ">ISC 2009</a>). Incontinence is a widespread problem in all healthcare settings (<a href="./references#CD011627-bbs2-0050" title="Du MoulinMF , HamersJP , AmbergenAW , JanssenMA , HalfensRJ . Prevalence of urinary incontinence among community‐dwelling adults receiving home care. Research in Nursing &amp; Health2008;31(6):604‐12. ">Du Moulin 2008</a>; <a href="./references#CD011627-bbs2-0063" title="MacmillanAK , MerrieAE , MarshallRJ , ParryBR . The prevalence of fecal incontinence in community‐dwelling adults: a systematic review of the literature. Diseases of the Colon and Rectum2004;47(8):1341‐9. ">Macmillan 2004</a>). Figures from studies on the prevalence of urinary/faecal incontinence vary, mainly attributable to the population type and the study protocol used. With prevalence estimates between 10% and 15% for faecal incontinence measured in community‐dwelling adults (<a href="./references#CD011627-bbs2-0063" title="MacmillanAK , MerrieAE , MarshallRJ , ParryBR . The prevalence of fecal incontinence in community‐dwelling adults: a systematic review of the literature. Diseases of the Colon and Rectum2004;47(8):1341‐9. ">Macmillan 2004</a>; <a href="./references#CD011627-bbs2-0068" title="ShamliyanT , WymanJ , BlissDZ , KaneRL , WiltTJ . Prevention of urinary and fecal Incontinence in adults. Evidence Report/Technology Assessment2007;161:1‐379. ">Shamliyan 2007</a>), and up to 46% for urinary incontinence measured in older, home care patients (<a href="./references#CD011627-bbs2-0050" title="Du MoulinMF , HamersJP , AmbergenAW , JanssenMA , HalfensRJ . Prevalence of urinary incontinence among community‐dwelling adults receiving home care. Research in Nursing &amp; Health2008;31(6):604‐12. ">Du Moulin 2008</a>), it is clear that incontinence care is an important task for clinicians, patients, and their carers. Incontinence can lead to numerous complications. One of the most common complications is perineal skin breakdown (<a href="./references#CD011627-bbs2-0054" title="GrayM . Optimal management of Incontinence‐associated dermatitis in the elderly. American Journal of Clinical Dermatology2010;11(3):201‐10. ">Gray 2010</a>; <a href="./references#CD011627-bbs2-0062" title="LangemoD , HansonD , HunterS , ThompsonP , OhIE . Incontinence and incontinence‐associated dermatitis. Advances in Skin &amp; Wound Care2011;24(3):124‐40. ">Langemo 2011</a>). </p> <section id="CD011627-sec-0032"> <h4 class="title">Incontinence‐associated dermatitis</h4> <p>We can define incontinence‐associated dermatitis (IAD) as erythema and oedema of the surface of the skin, sometimes accompanied by bullae with serous exudates, erosion, or secondary cutaneous infection. Skin exposed to moisture, such as faecal or urinary incontinence, is susceptible to the development of IAD. <a href="./references#CD011627-bbs2-0053" title="GrayM , BlissDZ , DoughtyDB , Ermer‐SeltunJ , Kennedy‐EvansKL , PalmerMH . Incontinence‐associated dermatitis: a consensus. Journal of Wound, Ostomy, and Continence Nursing2007;34(1):45‐54. ">Gray 2007</a> defined IAD as a skin inflammation manifested as redness with or without blistering, erosion, or loss of the skin barrier function that occurs as a consequence of chronic or repeated exposure of the skin to urine or faecal matter. IAD is the result of top‐down damage to the skin due to: </p> <p> <ul id="CD011627-list-0001"> <li> <p>tissue intolerance (e.g. age, nutrition);</p> </li> <li> <p>an affected perineal environment (e.g. due to incontinence); and</p> </li> <li> <p>problems with toileting ability (e.g. restraints) (<a href="./references#CD011627-bbs2-0043" title="BeeckmanD , SchoonhovenL , VerhaegheS , HeynemanA , DefloorT . Prevention and treatment of incontinence‐associated dermatitis: Literature review. Journal of Advanced Nursing2009;65(6):1141‐54. ">Beeckman 2009</a>). </p> </li> </ul> </p> <p>The most important aetiologic factors are urinary, faecal, and double incontinence (<a href="./references#CD011627-bbs2-0045" title="BeeckmanD , VanLanckerA , VanHeckeA , VerhaegheS . A systematic review and meta‐analysis of incontinence‐associated dermatitis, incontinence, and moisture as risk factors for pressure ulcer development. Nursing in Research &amp; Health2014;37(3):204‐18. ">Beeckman 2014</a>). Faecal incontinence has been identified as a particularly high risk factor for the development of IAD, with liquid faecal matter as the most severe irritant (<a href="./references#CD011627-bbs2-0043" title="BeeckmanD , SchoonhovenL , VerhaegheS , HeynemanA , DefloorT . Prevention and treatment of incontinence‐associated dermatitis: Literature review. Journal of Advanced Nursing2009;65(6):1141‐54. ">Beeckman 2009</a>). </p> <p>Traditionally, IAD has received little attention as a distinct skin disorder, and it is regularly confused with Category/Stage I and II pressure ulcers (<a href="./references#CD011627-bbs2-0044" title="BeeckmanD , SchoonhovenL , FletcherJ , FurtadoK , HeymanH , PaquayL . Pressure ulcers and incontinence‐associated dermatitis: Effectiveness of the pressure ulcer classification education tool on classification by nurses. Quality and Safety in Health Care2010;19(5):e3. ">Beeckman 2010</a>; <a href="./references#CD011627-bbs2-0045" title="BeeckmanD , VanLanckerA , VanHeckeA , VerhaegheS . A systematic review and meta‐analysis of incontinence‐associated dermatitis, incontinence, and moisture as risk factors for pressure ulcer development. Nursing in Research &amp; Health2014;37(3):204‐18. ">Beeckman 2014</a>). The clinical presentation of IAD ranges from erythema (with or without loss of skin) to cutaneous infections (such as candidiasis) (<a href="./references#CD011627-bbs2-0042" title="BeeckmanD , SchoonhovenL , FletcherJ , FurtadoK , GunningbergL , HeymanH , et al. EPUAP classification system for pressure ulcers: European Reliability Study. Journal of Advanced Nursing2007;60(5):682‐91. ">Beeckman 2007</a>). IAD is often associated with redness, rash, or vesiculation (<a href="./references#CD011627-bbs2-0053" title="GrayM , BlissDZ , DoughtyDB , Ermer‐SeltunJ , Kennedy‐EvansKL , PalmerMH . Incontinence‐associated dermatitis: a consensus. Journal of Wound, Ostomy, and Continence Nursing2007;34(1):45‐54. ">Gray 2007</a>). Although the lesions are superficial, they are likely to become slightly deeper when an infection occurs. In contrast, the clinical signs of pressure ulcers range from non‐blanchable erythema of the intact skin, over partial/full thickness skin loss, to tissue destruction involving skin, subcutaneous fat, muscle, and bone (<a href="./references#CD011627-bbs2-0065" title="National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel, Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers: Quick Reference Guide. 2nd Edition. Perth: Cambridge Media, 2014. [Available at NPUAP‐EPUAP‐PPPIA Pressure Ulcer Treatment &amp; Prevention, 2014 Quick Reference Guide] ">NPUAP 2014</a>). A recent systematic review and meta‐analysis by <a href="./references#CD011627-bbs2-0045" title="BeeckmanD , VanLanckerA , VanHeckeA , VerhaegheS . A systematic review and meta‐analysis of incontinence‐associated dermatitis, incontinence, and moisture as risk factors for pressure ulcer development. Nursing in Research &amp; Health2014;37(3):204‐18. ">Beeckman 2014</a> confirmed incontinence (and moisture in general) and IAD as an important risk factor for pressure ulcer development. </p> <section id="CD011627-sec-0033"> <h5 class="title">Prevalence</h5> <p>Studies report prevalence figures of IAD between 5.6% to 50.0%, with incidence rates between 3.4% and 25.0%, depending on the type of setting and population studied (<a href="./references#CD011627-bbs2-0053" title="GrayM , BlissDZ , DoughtyDB , Ermer‐SeltunJ , Kennedy‐EvansKL , PalmerMH . Incontinence‐associated dermatitis: a consensus. Journal of Wound, Ostomy, and Continence Nursing2007;34(1):45‐54. ">Gray 2007</a>). Most epidemiological studies were performed in small sample, single‐centre, and long‐term care settings (<a href="./references#CD011627-bbs2-0055" title="GrayM , BeeckmanD , BlissDZ , FaderM , LoganS , JunkinJ , et al. Incontinence‐associated dermatitis: a comprehensive review and update. Journal of Wound, Ostomy, and Continence Nursing2012;39(1):61‐74. ">Gray 2012</a>). A study on the prevalence of IAD among hospitalised acute care patients in the United States (n = 976) reported a prevalence of 27% (<a href="./references#CD011627-bbs2-0059" title="JunkinJ , SelekofJ . Prevalence of incontinence and associated skin Injury in the acute care Inpatient. Journal of Wound, Ostomy, and Continence Nursing2007;34(3):260‐9. ">Junkin 2007</a>). A study using a large sample (n = 3713) of incontinent participants reported an overall IAD prevalence across different healthcare settings in two European countries of 6.1% (<a href="./references#CD011627-bbs2-0060" title="KottnerJ , Blume‐PeytaviU , LohrmannC , HalfensR . Associations between individual characteristics and incontinence‐associated dermatitis: a secondary data analysis of a multicentre prevalence study. International Journal of Nursing Studies 2014 Feb 23 [epub ahead of print]. [DOI: 10.1016/j.ijnurstu.2014.02.012] ">Kottner 2014</a>). Approximately one‐third of people with faecal incontinence develop IAD (<a href="./references#CD011627-bbs2-0052" title="GrayM , RatliffC , DonovanA . Perineal skin care for the incontinent patient. Advances in Skin &amp; Wound Care2002;15(4):170‐8. ">Gray 2002</a>). Incontinence, and subsequent skin breakdown, have a considerable effect on patients‘ physical and psychological well‐being (<a href="./references#CD011627-bbs2-0064" title="NewmanD , PrestonA , SalazarS . Moisture control, urinary and faecal incontinence, and perineal skin management. In: KrasnerD , RodeheaverG , SibbaldR editor(s). Chronic Wound Care: A Clinical Source Book for Healthcare Professionals. 4th Edition. Malvern: HMP Communications, 2007. ">Newman 2007</a>; <a href="./references#CD011627-bbs2-0069" title="SibbaldR , CampbellK , CouttsP , QueenD . Intact Skin ‐ an integrity not to be lost. Ostomy/Wound Management2003;49(6):27‐33. ">Sibbald 2003</a>). </p> </section> <section id="CD011627-sec-0034"> <h5 class="title">Aetiology</h5> <p>The aetiology of IAD is complex and related to both chemical and physical irritation of the skin (<a href="./references#CD011627-bbs2-0043" title="BeeckmanD , SchoonhovenL , VerhaegheS , HeynemanA , DefloorT . Prevention and treatment of incontinence‐associated dermatitis: Literature review. Journal of Advanced Nursing2009;65(6):1141‐54. ">Beeckman 2009</a>). <a href="./references#CD011627-bbs2-0041" title="AnanthapadmanabhanK , MooreD , SubramanyanK , MisraM , MeyerF . Cleansing without compromise: the impact of cleansers on the skin barrier and the technology of mild cleansing. Dermatology and Therapy2004;17:16‐25. ">Ananthapadmanabhan 2004</a> demonstrated that a rise in pH (caused by urine and faeces) increases stratum corneum swelling and alterations in lipid rigidity, thus increasing the permeability of the skin and reducing the barrier function. Furthermore, a more alkaline pH increases the risk of bacterial colonisation, and thus cutaneous infections. Friction (physical irritation) increases when the skin rubs over clothing, diapers/pads, and bed or chair surfaces. The combination of chemical and physical irritation results in a weakened skin. If these mechanisms affect the integrity of the skin recurrently, IAD and further skin breakdown are likely to develop (<a href="./references#CD011627-bbs2-0043" title="BeeckmanD , SchoonhovenL , VerhaegheS , HeynemanA , DefloorT . Prevention and treatment of incontinence‐associated dermatitis: Literature review. Journal of Advanced Nursing2009;65(6):1141‐54. ">Beeckman 2009</a>). </p> <p>To date, there has been a lack of rigorously performed research addressing the effectiveness of different skin care regimens to prevent or treat IAD. A number of studies compared the use and effects of different types of skin regimens, but design weaknesses seem to be common. Tentative evidence indicates that key prevention recommendations include structured skin care regimens including gentle cleansing, moisturising, and the application of skin protectants or moisture barriers. </p> </section> </section> </section> <section id="CD011627-sec-0035"> <h3 class="title" id="CD011627-sec-0035">Description of the intervention</h3> <p>Current prevention of IAD consists of skin care interventions such as skin cleansing, moisturising/skin conditioning, and the application of skin protectants/barriers. Treatment includes protecting the skin from further exposure to irritants, establishing a healing environment, and eradicating skin infections. A plethora of over‐the‐counter and prescribed products for cleansing, moisturising, and protecting (creams, ointments, pastes, film layers, etc.) as well as procedures to apply the products (for example, frequency and method of application) are currently available. The same products are used for patients with and without IAD. Topical antibiotics and antimycotics are additionally used to eradicate skin infections. </p> </section> <section id="CD011627-sec-0036"> <h3 class="title" id="CD011627-sec-0036">How the intervention might work</h3> <p>We considered three main interventions (cleansing, moisturising, protection) using topical skin care products in this Cochrane Review. We also investigated different procedures for their use, such as frequency or method of application. </p> <section id="CD011627-sec-0037"> <h4 class="title">Cleansing</h4> <p>Skin cleansing aims to remove dirt, debris, and micro‐organisms on the skin surface, usually using water alone or in combination with skin cleansers. </p> </section> <section id="CD011627-sec-0038"> <h4 class="title">Moisturising</h4> <p>Skin moisturising aims to repair or augment the skin's barrier, retain and/or increase its water content, reduce transepidermal water loss, and restore or improve the intercellular lipid structure. </p> </section> <section id="CD011627-sec-0039"> <h4 class="title">Protectants and barriers</h4> <p>The primary purpose of a skin protectant is to prevent skin breakdown by providing an impermeable or semipermeable barrier on the skin, thus preventing or reducing the penetration of water and chemical and biological irritants found in stool and urine. </p> </section> </section> <section id="CD011627-sec-0040"> <h3 class="title" id="CD011627-sec-0040">Why it is important to do this review</h3> <p>A wide range of topical skin care products and procedures are currently used in practice. Despite their widespread use, little is known about their efficacy and effectiveness. We conducted this review to clarify the effects of various products and skin care protocols to prevent and treat IAD in adults. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011627-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011627-sec-0041"></div> <p>The objective of this review was to assess the effectiveness of various products and procedures to prevent and treat incontinence‐associated dermatitis in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011627-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011627-sec-0042"></div> <section id="CD011627-sec-0043"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011627-sec-0044"> <h4 class="title">Types of studies</h4> <p>We included all RCTs and quasi‐RCTs if one arm of the trial included a structured and well‐defined procedure (including a standard frequency, method, and product selection) or a skin care product used to prevent or treat incontinence‐associated dermatitis (IAD). We compared these with other structured skin care procedures or unstructured (not standardised) procedures or other products, methods, or frequencies used to prevent or treat IAD. </p> </section> <section id="CD011627-sec-0045"> <h4 class="title">Types of participants</h4> <p>Studies involving male or female participants, or both, over 18 years of age, in any healthcare setting, with or without IAD (defined as erythema and oedema of the surface of the skin, sometimes accompanied by bullae with serous exudates, erosion, or secondary cutaneous infection) were eligible for inclusion. </p> </section> <section id="CD011627-sec-0046"> <h4 class="title">Types of interventions</h4> <p>We included trials of topical skin care products such as skin cleansers, moisturisers, and skin protectants of different compositions and skin care procedures aiming to prevent or treat IAD in this Cochrane Review. We examined the following comparisons. </p> <p> <ol id="CD011627-list-0002"> <li> <p>Any topical skin care product versus another topical skin care product.</p> <ol id="CD011627-list-0003"> <li> <p>Cleansing products</p> </li> <li> <p>Moisturising products</p> </li> <li> <p>Protectants and barriers</p> </li> </ol> </li> <li> <p>Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure. </p> </li> <li> <p>Any method of application of a topical skin care product versus another method of application of the topical skin care product. </p> </li> <li> <p>Any frequency of application of a topical skin care product versus another frequency of application of the topical skin care product. </p> </li> </ol> </p> </section> <section id="CD011627-sec-0047"> <h4 class="title">Types of outcome measures</h4> <section id="CD011627-sec-0048"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011627-list-0004"> <li> <p>Number of participants with incontinence‐associated dermatitis (IAD) (residual, i.e. not healed) </p> </li> <li> <p>Number of participants with IAD (new) (only suitable to evaluate interventions for preventing IAD) </p> </li> <li> <p>Number of participants not satisfied with treatment</p> </li> </ol> </p> </section> <section id="CD011627-sec-0049"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011627-list-0005"> <li> <p>Participants’ observations</p> <ol id="CD011627-list-0006"> <li> <p>Number of participants with pain due to IAD</p> </li> <li> <p>Number of participants with pain due to skin care product or procedure</p> </li> </ol> </li> <li> <p>Quantification of symptoms (objective measures)</p> <ol id="CD011627-list-0007"> <li> <p>Surface affected by IAD (measurement of size of lesion)</p> </li> </ol> </li> <li> <p>Clinicians' observations</p> <ol id="CD011627-list-0008"> <li> <p>Number of participants with IAD not improved (only suitable to evaluate interventions for treating IAD) </p> </li> <li> <p>Number of participants not complying/discontinuing treatment (acceptability and tolerance)</p> </li> </ol> </li> <li> <p>Quality of life</p> <ol id="CD011627-list-0009"> <li> <p>Condition‐specific</p> </li> <li> <p>Generic (e.g. SF‐36, EQ‐5D, Manchester Short Assessment of Quality of Life)</p> </li> <li> <p>Psychosocial</p> </li> </ol> </li> <li> <p>Economic data</p> <ol id="CD011627-list-0010"> <li> <p>Cost of products</p> </li> <li> <p>Staff time</p> </li> <li> <p>Incremental cost‐effectiveness</p> </li> </ol> </li> <li> <p>Adverse effects (of the interventions)</p> <ol id="CD011627-list-0011"> <li> <p>Adverse reaction due to the skin care product or procedure, e.g. skin irritation, rash, itching, allergic reaction </p> </li> <li> <p>Normal flora disruption</p> </li> <li> <p>Toxicity</p> </li> </ol> </li> <li> <p>Other outcomes (non‐prespecified outcomes judged important when performing the review)</p> <ol id="CD011627-list-0012"> <li> <p>IAD severity</p> </li> <li> <p>Number of participants with IAD completely healed</p> </li> <li> <p>Number of participants with bacterial or fungal infection</p> </li> </ol> </li> </ol> </p> </section> </section> </section> <section id="CD011627-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <p>We undertook a two‐step search strategy to identify relevant literature. Firstly, we searched electronic databases. Secondly, we searched other sources, such as conference proceedings. We imposed no restrictions, such as language or publication status, on the searches. </p> <section id="CD011627-sec-0051"> <h4 class="title">Electronic searches</h4> <p>This review drew on the search strategy developed for the Cochrane Incontinence Group. We identified relevant trials from the Cochrane Incontinence Group Specialised Trials Register. For more details of the search methods used to build the Specialised Register, please see the Group's <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/INCONT/frame.html" target="_blank">module</a> in the Cochrane Library. The register contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In‐Process, MEDLINE Epub Ahead of Print, CINAHL, <a href="http://clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a>, World Health Organisation International Clinical Trials Registry Platform (<a href="http://who.int/ictrp" target="_blank">WHO ICTRP</a>), and handsearching of journals and conference proceedings. Many of the trials in the Cochrane Incontinence Group Specialised Register are also contained in CENTRAL. </p> <p>The terms used to search the Cochrane Incontinence Group Specialised Register are given in <a href="./appendices#CD011627-sec-0153">Appendix 1</a>. The date of the last search was 28 September 2016. </p> <p>Additionally, as the condition can be very poorly described, especially in the older literature, we searched the following electronic databases. </p> <p> <ul id="CD011627-list-0013"> <li> <p>CENTRAL on OvidSP 2015, Issue 4 was searched on 27 May 2015. The search strategy is given in <a href="./appendices#CD011627-sec-0154">Appendix 2</a>. </p> </li> <li> <p>MEDLINE on OvidSP (from January 1946 to May Week 3, 2015) was searched on 27 May 2015. The search strategy is given in <a href="./appendices#CD011627-sec-0154">Appendix 2</a>. </p> </li> <li> <p>MEDLINE In‐Process on OvidSP (covering 26 May 2015) was searched on 27 May 2015. The search strategy is given in <a href="./appendices#CD011627-sec-0154">Appendix 2</a>. </p> </li> <li> <p>Cumulative Index for Nursing and Allied Health (CINAHL), was searched through the EBSCO Interface, from inception (December 1981) to the most recent version available (27 May 2015) on 28 May 2015. The search strategy is given in <a href="./appendices#CD011627-sec-0155">Appendix 3</a>. </p> </li> <li> <p>Web of Science (WoS) (on Web of Knowledge) was searched from inception of the constituent databases to the most recent available versions, on 28 May 2015. The search was limited to the WoS Core Collection. The search strategy is given in <a href="./appendices#CD011627-sec-0156">Appendix 4</a>. </p> </li> </ul> </p> </section> <section id="CD011627-sec-0052"> <h4 class="title">Searching other resources</h4> <p>The review authors contacted authors of trials included in this Cochrane Review and asked them if they knew of any other RCTs possibly relevant for this review. We also contacted experts in the field to identify additional trials. </p> <p>We handsearched the following conference proceedings: European Pressure Ulcer Advisory Panel (2000 to July 2015), European Wound Management Association (2001 to July 2015), and Wound, Ostomy and Continence Nurses Society (1994 to July 2015). </p> <p>We screened the reference lists of all included trials and other relevant literature reviews to identify additional papers. </p> </section> </section> <section id="CD011627-sec-0053"> <h3 class="title" id="CD011627-sec-0053">Data collection and analysis</h3> <section id="CD011627-sec-0054"> <h4 class="title">Selection of studies</h4> <p>Two review authors (NVD and KVDB) independently screened titles and abstracts of all identified records. They retrieved and further checked for inclusion the full text of all potentially relevant records. NVD and KVDB sought the advice of a third review author (AVL) to resolve disagreements and documented reasons for exclusion of the records read in full. </p> </section> <section id="CD011627-sec-0055"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (SW and JK) independently extracted data from the included trials. We developed a standardised form to use in this review. We pilot‐tested the extraction form to identify whether we should collect additional data or improve the form. </p> <p>The standardised form included the following data to be extracted: aim, design, setting, sample characteristics, description of intervention and comparison, outcome, and limitations. If necessary, we contacted the authors of the included studies to request additional information. </p> </section> <section id="CD011627-sec-0056"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We evaluated the methodological quality of all included articles using Cochrane's 'Risk of bias' tool. This includes the following: selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias (bias not covered elsewhere). We assigned each domain a judgement of ‘low risk’, ‘high risk’, or ‘unclear risk’ of bias, which we interpreted in accordance with Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011627-bbs2-0057" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Five review authors (MG, LS, JK, SW, DDM) independently assessed the risk of bias. If necessary, these authors sought the advice of DB to resolve disagreements. </p> </section> <section id="CD011627-sec-0057"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated risk ratios (RRs) with a 95% confidence interval (CI) for binary outcomes and mean differences (MDs) with a 95% CI for continuous data. </p> </section> <section id="CD011627-sec-0058"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis of RCTs and quasi‐RCTs were individual participants. If appropriate, we used the following choices for other designs. </p> <p> <ul id="CD011627-list-0014"> <li> <p>Cross‐over design: we planned to use the first treatment period.</p> </li> <li> <p>Cluster‐RCTs: we took into account the clustering effect.</p> </li> </ul> </p> </section> <section id="CD011627-sec-0059"> <h4 class="title">Dealing with missing data</h4> <p>The review authors contacted the authors of studies with missing data to request additional information. We used the intention‐to‐treat analysis (defined as analysed in the group to which the participants were randomised whether or not they received the intervention) and available case analysis (that is data as reported by trialists without imputation for missing data).If data were missing to the extent that we could not include the trial in the analysis, we presented the results in a narrative way. If there was evidence of differential dropout, we gave consideration to imputation of the missing data. </p> </section> <section id="CD011627-sec-0060"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to combine the studies in a meta‐analysis if the clinical and methodological heterogeneity were acceptable. We judged the clinical heterogeneity based on population and intervention type. Due to large clinical and methodological heterogeneity, the data were not suitable for meta‐analysis. </p> <p>We planned to assess the statistical heterogeneity using the Chi² test at a significance level of 0.10 and calculate the I² statistic to quantify the heterogeneity. We would interpret the I² in accordance with Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011627-bbs2-0057" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), and we would explore the source of heterogeneity using subgroup and sensitivity analysis. However, we did not perform a Chi² test nor calculated the I² statistic because a meta‐analysis was not suitable. </p> </section> <section id="CD011627-sec-0061"> <h4 class="title">Assessment of reporting biases</h4> <p>A comprehensive search for eligible studies and alertness for duplication of data minimised the potential impact of publication and reporting bias. It was not possible to perform a funnel plot to assess reporting bias because of non‐comparable designs and outcomes. </p> </section> <section id="CD011627-sec-0062"> <h4 class="title">Data synthesis</h4> <p>We entered data of all the trials in the software program Review Manager (<a href="./references#CD011627-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>We planned to use a fixed‐effect model when pooling the data, except for studies with an I² equal to or greater than 75%, in which case we would use a random‐effects model. However, due to large clinical and methodological heterogeneity, it was not suitable to pool data. We presented the results in a narrative way. </p> <p>We rated the quality of the evidence by using the software program GRADEpro (<a href="./references#CD011627-bbs2-0051" title="GRADE Working Group, McMaster University. GRADEpro GDT. Hamilton (ON): GRADE Working Group, McMaster University, (Accessed 13 April 2016). ">GRADEpro GDT 2014</a>). We assessed the relevance of the effect of the interventions based on a judgment of each participant‐important outcome separately. GRADE allowed us to assess the quality of the body of evidence by taking into account five considerations: study limitations, consistency of effect, imprecision, indirectness, and publication bias (<a href="./references#CD011627-bbs2-0056" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395‐400. ">Guyatt 2011</a>).The GRADE working group strongly recommends including up to seven potentially participant‐important outcomes in a systematic review (<a href="./references#CD011627-bbs2-0056" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395‐400. ">Guyatt 2011</a>). Based on discussion within the research group, the review authors selected the following potentially important participant outcomes. </p> <p> <ol id="CD011627-list-0015"> <li> <p>Number of participants with IAD (residual).</p> </li> <li> <p>Number of participants with IAD (new).</p> </li> <li> <p>Number of participants not satisfied with treatment.</p> </li> <li> <p>Number of participants with pain due to IAD.</p> </li> <li> <p>Number of participants with pain due to skin care product or procedure.</p> </li> <li> <p>Adverse reaction due to the skin care product or procedure, e.g. skin irritation, rash, itching, allergic reaction. </p> </li> <li> <p>Incremental cost‐effectiveness.</p> </li> </ol> </p> <p>We presented participant‐important outcomes in <a href="./full#CD011627-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD011627-tbl-0002">summary of findings Table 2</a>. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011627-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011627-sec-0063"></div> <section id="CD011627-sec-0064"> <h3 class="title">Description of studies</h3> <section id="CD011627-sec-0065"> <h4 class="title">Results of the search</h4> <p>The literature search produced 4089 records, from which we further assessed 40 full‐text articles for eligibility. Fourteen (quasi) randomised trials met the inclusion criteria for this review. One of these studies is awaiting classification, as Japanese translation is needed (<a href="./references#CD011627-bbs2-0038" title="KajiiF , UchidaE , KameiT , TanakaJ , KushiroW . Development of a preventive skin care protocol using a skin protection cleaning foam for frail elderly who had urinary and fecal incontinence. Bulletin of St. Luke's College of Nursing2005;31:26‐35. ">Kajii 2005</a>; <a href="./references#CD011627-sec-0172" title="">Characteristics of studies awaiting classification</a>). Additionally there were two ongoing studies (<a href="./references#CD011627-bbs2-0039" title="NCT02570139 . Multi‐center, randomized trial comparing the efficacy of 3M™ Cavilon™ Advanced Barrier Film for the treatment of incontinence‐associated dermatitis to a commercially available moisture barrier. https://clinicaltrials.gov/show/NCT02570139 (accessed 29 September 2016)2015. ">NCT02570139 2015</a>; <a href="./references#CD011627-bbs2-0040" title="NCT02690753 . A turn and positioning system and standardized incontinence care combined with tailored repositioning versus a standard repositioning protocol for pressure ulcer prevention: a multicenter prospective randomized controlled clinical trial and health economical analysis in a hospital setting. https://clinicaltrials.gov/show/NCT02690753 (accessed 29 September 2016)2016. ">NCT02690753 2016</a>). The PRISMA diagram in <a href="#CD011627-fig-0001">Figure 1</a> presents the flow of the literature search. </p> <div class="figure" id="CD011627-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram." data-id="CD011627-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> </div> </section> <section id="CD011627-sec-0066"> <h4 class="title">Included studies</h4> <p>We included 13 (quasi‐)RCTs in the qualitative synthesis (see <a href="./references#CD011627-sec-0170" title="">Characteristics of included studies</a>). The total number of participants included in the analyses was 1295. </p> <p><b>Design</b> </p> <p>Eleven trials had a parallel group design. One trial had a cluster design (<a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a>). One trial had a cross‐over design without a washout period between treatments (<a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a>). </p> <p><b>Settings</b> </p> <p>Nine trials were performed at single centres. Of these, six were located in the United States, one in the Philippines, one in China, and one in the Netherlands. Five of these single‐centre studies were conducted in hospitals and four in nursing homes. </p> <p>One trial was conducted on geriatric wards of hospitals from one health service trust in the United Kingdom.<br/> Of the three remaining trials, one was conducted in 11 nursing homes in Belgium, one in 22 nursing homes in the Netherlands, and one in five long‐term care centres in the United States. </p> <p><b>Participants</b> </p> <p>The mean age of the participants varied between 59 and 89 years across all studies. In more than half of the trials (7/13), the mean age was over 80 years. In the <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a> trial, conducted in a nursing home, the participants were between 41 and 105 years old. Two other trials, of which one was conducted in a hospital and one in a nursing home, did not report data on participants' age (<a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a>; <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>). </p> <p>Most of the trials (n = 10) recruited participants with all types of incontinence. In one trial, participants with faecal incontinence were included (<a href="./references#CD011627-bbs2-0013" title="WangY , ZhuX , ZhouM . Comparative observation of Dermlin and Genetime used for fecal incontinence patients with perianal skin damage. Chinese Nursing Research2011;25(3C):776‐7. [sr‐incont42528] ">Wang 2011</a>). In another trial, only female participants with both urinary and faecal incontinence were included (<a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a>). In a last trial, the type of incontinence was not reported (<a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a>). </p> <p>In six trials, more than half of the participants showed neither redness nor skin erosion. Two trials included only participants without redness or skin erosion (<a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a>; <a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a>). Three trials included only participants with redness and/or skin erosion (<a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>; <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a>; <a href="./references#CD011627-bbs2-0013" title="WangY , ZhuX , ZhouM . Comparative observation of Dermlin and Genetime used for fecal incontinence patients with perianal skin damage. Chinese Nursing Research2011;25(3C):776‐7. [sr‐incont42528] ">Wang 2011</a>). The two remaining trials did not report the proportion of participants with skin problems in the perineal environment (<a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a>; <a href="./references#CD011627-bbs2-0012" title='SchoonhovenL , vanGaalBG , TeerenstraS , AdangE , van derVleutenC , vanAchterbergT . Cost‐consequence analysis of "washing without water" for nursing home residents: a cluster randomized trial. International Journal of Nursing Studies2015;52(1):112‐20. '>Schoonhoven 2015</a>). </p> <p><b>Interventions</b> </p> <p>Eight trials compared the application of a topical skin care product versus another topical skin care product for the prevention and/or treatment of incontinence‐associated dermatitis (IAD) (first comparison, see <a href="#CD011627-sec-0046">Types of interventions</a>). Because the main function of the products (moisturising versus skin protecting) was not always clear, we classified all topical skin care products broadly into skin cleansers and leave‐on products. Leave‐on products include moisturisers, skin protectants/barriers, and other functions, whether combined or not into one product. </p> <p> <ul id="CD011627-list-0016"> <li> <p>Two trials compared no‐rinse skin cleansers with soap and water for the prevention (and treatment) of IAD (<a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a>; <a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a>). </p> </li> </ul> <ul id="CD011627-list-0017"> <li> <p>Eight trials compared various leave‐on products (moisturisers, skin protectants/barriers, whether combined or not into one product) as follows. </p> </li> </ul> <ul class="plain" id="CD011627-list-0018"> <li> <ul id="CD011627-list-0019"> <li> <p>One trial compared Sudocrem with a standard zinc oxide cream for the prevention and treatment of IAD (<a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a>). </p> </li> <li> <p>A second trial compared a zinc oxide oil with a film‐forming skin product for the prevention and treatment of IAD (<a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>). </p> </li> <li> <p>A third trial compared a no‐rinse skin cleanser and a leave‐on product with a washcloth with cleansing, moisturising and skin protecting properties for the prevention and treatment of IAD (<a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a>). </p> </li> <li> <p>A fourth trial compared a no‐rinse skin cleanser and a skin cream with soap and water combined with a lotion for the prevention and treatment of IAD (<a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a>). </p> </li> <li> <p>A fifth trial compared a no‐rinse skin cleanser and moisturiser combined with a film‐forming skin product with a cleansing/moisturising/skin protecting washcloth for the prevention of IAD (<a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a>). </p> </li> <li> <p>A sixth trial compared Desitin and Calmoseptine, two commercial zinc oxide based products, for the treatment of IAD (<a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a>). </p> </li> <li> <p>A seventh trial compared a zinc oxide cream with a petrolatum ointment and a film‐forming skin product for the treatment of IAD (<a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>). </p> </li> <li> <p>An eighth trial compared Dermlin and Genetime for the treatment of IAD (<a href="./references#CD011627-bbs2-0013" title="WangY , ZhuX , ZhouM . Comparative observation of Dermlin and Genetime used for fecal incontinence patients with perianal skin damage. Chinese Nursing Research2011;25(3C):776‐7. [sr‐incont42528] ">Wang 2011</a>). </p> </li> </ul> </li> </ul> </p> <p>Two trials compared a structured skin care procedure with an unstructured skin care procedure (second comparison, see <a href="#CD011627-sec-0046">Types of interventions</a>). </p> <p> <ul id="CD011627-list-0020"> <li> <p>One trial compared a washcloth with cleansing, moisturising, and protecting properties with soap and water for the prevention and treatment of IAD (<a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a>). </p> </li> <li> <p>One trial compared a washcloth impregnated with a lotion with soap and water for the prevention and treatment of any skin abnormalities and significant skin lesions (<a href="./references#CD011627-bbs2-0012" title='SchoonhovenL , vanGaalBG , TeerenstraS , AdangE , van derVleutenC , vanAchterbergT . Cost‐consequence analysis of "washing without water" for nursing home residents: a cluster randomized trial. International Journal of Nursing Studies2015;52(1):112‐20. '>Schoonhoven 2015</a>). </p> </li> </ul> </p> <p>Two trials compared different frequencies of application of topical skin care products (fourth comparison, see <a href="#CD011627-sec-0046">Types of interventions</a>). </p> <p> <ul id="CD011627-list-0021"> <li> <p>One trial compared two frequencies of a structured skin care procedure, including a skin cleanser and a leave‐on product, for the prevention and treatment of IAD: every six versus 12 hours (<a href="./references#CD011627-bbs2-0007" title="ConleyP , McKinseyD , RossO , RamseyA , FeebackJ . Does skin care frequency affect the severity of incontinence‐associated dermatitis in critically ill patients?. Nursing2014;44(12):27‐32. [sr‐incont64906] ">Conley 2014</a>). </p> </li> <li> <p>One trial compared three frequencies of the application of a film‐forming skin product in the treatment of IAD: every 24 and 48 hours versus 72 hours for the treatment of IAD (<a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>). </p> </li> </ul> </p> <p><b>Length of treatment</b> </p> <p>Most trials (n = 9) had a treatment period of 15 days or less. In three trials, nursing home residents were treated for three weeks (<a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a>), six weeks (<a href="./references#CD011627-bbs2-0012" title='SchoonhovenL , vanGaalBG , TeerenstraS , AdangE , van derVleutenC , vanAchterbergT . Cost‐consequence analysis of "washing without water" for nursing home residents: a cluster randomized trial. International Journal of Nursing Studies2015;52(1):112‐20. '>Schoonhoven 2015</a>), or three months (<a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a>). In one trial the length of treatment was not reported (<a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a>). </p> <p><b>Sample size</b> </p> <p>Four trials had a sample size of 50 or less participants (<a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>; <a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a>; <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a>; <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>). In six trials, the sample size varied between 50 and 100 (<a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a>; <a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a>; <a href="./references#CD011627-bbs2-0007" title="ConleyP , McKinseyD , RossO , RamseyA , FeebackJ . Does skin care frequency affect the severity of incontinence‐associated dermatitis in critically ill patients?. Nursing2014;44(12):27‐32. [sr‐incont64906] ">Conley 2014</a>; <a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a>; <a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a>; <a href="./references#CD011627-bbs2-0013" title="WangY , ZhuX , ZhouM . Comparative observation of Dermlin and Genetime used for fecal incontinence patients with perianal skin damage. Chinese Nursing Research2011;25(3C):776‐7. [sr‐incont42528] ">Wang 2011</a>). In three trials, more than 100 participants were included (<a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a>; <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a>; <a href="./references#CD011627-bbs2-0012" title='SchoonhovenL , vanGaalBG , TeerenstraS , AdangE , van derVleutenC , vanAchterbergT . Cost‐consequence analysis of "washing without water" for nursing home residents: a cluster randomized trial. International Journal of Nursing Studies2015;52(1):112‐20. '>Schoonhoven 2015</a>). The smallest sample size was 10 (<a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a>), and the largest 450 (<a href="./references#CD011627-bbs2-0012" title='SchoonhovenL , vanGaalBG , TeerenstraS , AdangE , van derVleutenC , vanAchterbergT . Cost‐consequence analysis of "washing without water" for nursing home residents: a cluster randomized trial. International Journal of Nursing Studies2015;52(1):112‐20. '>Schoonhoven 2015</a>). Only the trial of <a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a>, with a sample size of 141 participants, mentioned that this sample size was sufficient for a statistical power of 0.85 (α = 0.05). </p> <section id="CD011627-sec-0067"> <h5 class="title">Ongoing Studies</h5> <p>There are two ongoing studies (<a href="./references#CD011627-bbs2-0039" title="NCT02570139 . Multi‐center, randomized trial comparing the efficacy of 3M™ Cavilon™ Advanced Barrier Film for the treatment of incontinence‐associated dermatitis to a commercially available moisture barrier. https://clinicaltrials.gov/show/NCT02570139 (accessed 29 September 2016)2015. ">NCT02570139 2015</a>; <a href="./references#CD011627-bbs2-0040" title="NCT02690753 . A turn and positioning system and standardized incontinence care combined with tailored repositioning versus a standard repositioning protocol for pressure ulcer prevention: a multicenter prospective randomized controlled clinical trial and health economical analysis in a hospital setting. https://clinicaltrials.gov/show/NCT02690753 (accessed 29 September 2016)2016. ">NCT02690753 2016</a>). </p> </section> </section> <section id="CD011627-sec-0068"> <h4 class="title">Excluded studies</h4> <p>In total, we excluded 24 trials from this review (see <a href="./references#CD011627-sec-0171" title="">Characteristics of excluded studies</a>), for the following reasons. </p> <p> <ul id="CD011627-list-0022"> <li> <p>Six trials were not quasi‐RCTs (<a href="./references#CD011627-bbs2-0018" title="BlissDZ , ZehrerC , SavikK , SmithG , HedblomE . An economic evaluation of four skin damage prevention regimens in nursing home residents with incontinence: economics of skin damage prevention. Journal of Wound, Ostomy, and Continence Nursing2007;34(2):143‐52. ">Bliss 2007</a>; <a href="./references#CD011627-bbs2-0020" title="DealeyC . Pressure sores and incontinence: a study evaluating the use of topical agents in skin care. Journal of Wound Care1995;4(3):103‐5. ">Dealey 1995</a>; <a href="./references#CD011627-bbs2-0024" title="HolroydS , GrahamK . Prevention and management of incontinence‐associated dermatitis using a barrier cream. British Journal of Community Nursing. Suppl Wound Care2014;Suppl 12:S32‐8. ">Holroyd 2014</a>; <a href="./references#CD011627-bbs2-0027" title="KyungHP , KeumSK . Effect of a structured skin care regimen on patients with fecal incontinence. Journal of Wound, Ostomy, and Continence Nursing2014;41(2):161‐7. ">Kyung 2014</a>; <a href="./references#CD011627-bbs2-0029" title="LyderCH , Clemes‐LowranceC , DavisA , SullivanL , ZuckerA . Structured skin care regimen to prevent perineal dermatitis in the elderly. Journal of ET Nursing1992;19(1):12‐6. ">Lyder 1992</a>, <a href="./references#CD011627-bbs2-0037" title="ZehrerCL , LutzJB , HedblomEC , DingL . A comparison of cost and efficacy of three incontinence skin barrier products. Ostomy Wound Management2004;50(12):51‐8. ">Zehrer 2004</a>). </p> </li> <li> <p>Twelve trials did not encompass any topical skin care product (<a href="./references#CD011627-bbs2-0014" title="Al‐SamarraiNR , UmanGC , Al‐SamarraiT , AlessiCA . Introducing a new incontinence management system for nursing home residents. Journal of the American Medical Directors Association2007;8(4):253‐61. ">Al‐Samarrai 2007</a>; <a href="./references#CD011627-bbs2-0015" title="Bates‐JensenBM , AlessiCA , Al SamarraiNR , SchnelleJF . The effects of an exercise and incontinence intervention on skin health outcomes in nursing home residents. Journal of the American Geriatrics Society2003;51(3):348‐55. ">Bates‐Jensen 2003</a>; <a href="./references#CD011627-bbs2-0017" title="BennettRG , BaranPJ , DeVoneLV , BacettiH , KristoB , TaybackM , et al. Low airloss hydrotherapy versus standard care for incontinent hospitalized patients. Journal of the American Geriatrics Society1998;46(5):569‐76. ">Bennett 1998</a>; <a href="./references#CD011627-bbs2-0019" title="BrownDS . Diapers and underpads, part 1: skin integrity outcomes. Ostomy Wound Management1994;40(9):20‐8. ">Brown 1994</a>; <a href="./references#CD011627-bbs2-0021" title="DenatY , KhorshidL . The effect of 2 different care products on incontinence‐associated dermatitis in patients with fecal incontinence. Journal of Wound, Ostomy, and Continence Nursing2011;38(2):171‐6. ">Denat 2011</a>; <a href="./references#CD011627-bbs2-0022" title="FaderM , Clarke‐O'NeillS , CookD , DeanG , BrooksR , CottendenA , et al. Management of night‐time urinary incontinence in residential settings for older people: an investigation into the effects of different pad changing regimes on skin health. Journal of Clinical Nursing2003;12(3):374‐86. ">Fader 2003</a>; <a href="./references#CD011627-bbs2-0028" title="LeibyDM , ShanahanN . Clinical study: assessing the performance and skin environments of two reusable underpads. Ostomy Wound Management1994;40(8):30‐7. ">Leiby 1994</a>; <a href="./references#CD011627-bbs2-0031" title="Netta‐TurnerD , BucherL , DixonL , LaytonNJ . Riding the research roller coaster: what went right, what went wrong?. Journal of Wound, Ostomy, and Continence Nursing2008;35(5):469‐75. ">Netta‐Turner 2008</a>; <a href="./references#CD011627-bbs2-0033" title="PittmanJ , BeesonT , TerryC , KesslerW , KirkL . Methods of bowel management in critical care: a randomized controlled trial. Journal of Wound, Ostomy, and Continence Nursing2012;39(6):633‐9. ">Pittman 2012</a>; <a href="./references#CD011627-bbs2-0034" title="ShinYS , KimHJ , MoonNK , AhnYH , KimKO . The effects of uncoated paper on skin moisture and transepidermal water loss in bedridden patients. Journal of Clinical Nursing2012;21(17‐18):2469‐76. ">Shin 2012</a>; <a href="./references#CD011627-bbs2-0035" title="SuMY , LinSQ , ZhouYW , LiuSY , LinA , LinXR . A prospective, randomized, controlled study of a suspension positioning system used with elderly bedridden patients with neurogenic fecal incontinence. Ostomy Wound Management2015;61(1):30‐9. ">Su 2015</a>; <a href="./references#CD011627-bbs2-0036" title="SugamaJ , SanadaH , ShigetaY , NakagamiG , KonyaC . Efficacy of an improved absorbent pad on incontinence‐associated dermatitis in older women: cluster randomized controlled trial. BMC Geriatrics2012;12:22. ">Sugama 2012</a>). </p> </li> <li> <p>One trial was not developed for the prevention or treatment of IAD (<a href="./references#CD011627-bbs2-0032" title="PinedoG , ZarateAJ , InostrozaG , MenesesX , FallouxE , MolinaO , et al. New treatment for faecal incontinence using zinc‐aluminium ointment: a double‐blind randomized trial. Colorectal Disease2012;14(5):596‐8. ">Pinedo 2012</a>). </p> </li> <li> <p>One trial was restricted to the trial protocol (<a href="./references#CD011627-bbs2-0016" title="BauerC , GalvinEA , KuroskyA , DiBiaseRJ , MillerS . Testing the efficacy of two products for the prevention of perineal dermatitis in immune compromised patients: a randomized clinical trial. Oncology Nursing Forum2007;34(1):218. [sr‐incont67957] ">Bauer 2007</a>). </p> </li> <li> <p>Two trials included participants younger than 18 years (<a href="./references#CD011627-bbs2-0025" title="IrajiF , RezazadehM . The efficacy of topical sucralfate in comparison with hydrocortizone cream in the treatment of diaper dermatitis: a randomized, double blind clinical trial. Iranian Journal of Dermatology2003;3(6):8‐12. ">Iraji 2003</a>; <a href="./references#CD011627-bbs2-0026" title="JamesWS . A new use for an old ointment: Lantiseptic ointment as a treatment for diaper dermatitis. Journal of the Medical Association of Georgia1975;64(5):132‐3. ">James 1975</a>). </p> </li> <li> <p>One trial concerned the effectiveness of implementation strategies not effectiveness of products/procedures (<a href="./references#CD011627-bbs2-0023" title="HarriesFJ , BeggPA . Non‐rinse skin cleansers: the way forward in preventing incontinence related moisture lesions?. Journal of Wound Care2016;25(5):268‐76. ">Harries 2016</a>) </p> </li> <li> <p>One trial was finished prematurely, no reliable results were possible (<a href="./references#CD011627-bbs2-0030" title="NCT02475512 , BeeckmanD . A total body wash wipe combined with a genital wipe versus standard care (water and pH neutral soap) for washing of incontinent residents in a long‐term care setting: a multicenter prospective randomised controlled clinical trial and health economical analysis in nursing homes. https://clinicaltrials.gov/show/NCT024755122015. ">NCT02475512 2015</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011627-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD011627-sec-0070"> <h4 class="title">Allocation</h4> <p>The risk of bias associated with random sequence generation was low in five trials (<a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>; <a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a>; <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a>; <a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a>; <a href="./references#CD011627-bbs2-0012" title='SchoonhovenL , vanGaalBG , TeerenstraS , AdangE , van derVleutenC , vanAchterbergT . Cost‐consequence analysis of "washing without water" for nursing home residents: a cluster randomized trial. International Journal of Nursing Studies2015;52(1):112‐20. '>Schoonhoven 2015</a>), high in three trials (<a href="./references#CD011627-bbs2-0007" title="ConleyP , McKinseyD , RossO , RamseyA , FeebackJ . Does skin care frequency affect the severity of incontinence‐associated dermatitis in critically ill patients?. Nursing2014;44(12):27‐32. [sr‐incont64906] ">Conley 2014</a>; <a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a>; <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a>), and remained unclear in five trials (<a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a>; <a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a>; <a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a>; <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>; <a href="./references#CD011627-bbs2-0013" title="WangY , ZhuX , ZhouM . Comparative observation of Dermlin and Genetime used for fecal incontinence patients with perianal skin damage. Chinese Nursing Research2011;25(3C):776‐7. [sr‐incont42528] ">Wang 2011</a>). <a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a> used a computerised randomisation list provided by an independent biostatistics centre. <a href="./references#CD011627-bbs2-0012" title='SchoonhovenL , vanGaalBG , TeerenstraS , AdangE , van derVleutenC , vanAchterbergT . Cost‐consequence analysis of "washing without water" for nursing home residents: a cluster randomized trial. International Journal of Nursing Studies2015;52(1):112‐20. '>Schoonhoven 2015</a> used a computerised randomisation list set up by an independent statistician. <a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a> and <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a> performed a computerised randomisation at their own research centre. <a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a> used unmarked envelopes to randomise patients (first research site) or wards (other research sites). <a href="./references#CD011627-bbs2-0007" title="ConleyP , McKinseyD , RossO , RamseyA , FeebackJ . Does skin care frequency affect the severity of incontinence‐associated dermatitis in critically ill patients?. Nursing2014;44(12):27‐32. [sr‐incont64906] ">Conley 2014</a> assigned participants enrolled on even numbered days to the intervention group and those enrolled on odd numbered days to the control group. <a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a> assigned participants based on the last digit of their medical record number. <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a> assigned participants in odd numbered rooms to the trial protocol and participants in even numbered rooms to the control group. The methods used by <a href="./references#CD011627-bbs2-0007" title="ConleyP , McKinseyD , RossO , RamseyA , FeebackJ . Does skin care frequency affect the severity of incontinence‐associated dermatitis in critically ill patients?. Nursing2014;44(12):27‐32. [sr‐incont64906] ">Conley 2014</a>, <a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a> and <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a> were associated with a high risk of bias because allocation could be foreseen. </p> <p>The risk of bias associated with allocation concealment was low in one trial (<a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a>), high in three trials (<a href="./references#CD011627-bbs2-0007" title="ConleyP , McKinseyD , RossO , RamseyA , FeebackJ . Does skin care frequency affect the severity of incontinence‐associated dermatitis in critically ill patients?. Nursing2014;44(12):27‐32. [sr‐incont64906] ">Conley 2014</a>; <a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a>; <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a>), and remained unclear in the remaining nine trials. In the study of <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a>, an independent surgical research unit, not linked to the trialists, performed the treatment allocation. <a href="./references#CD011627-bbs2-0007" title="ConleyP , McKinseyD , RossO , RamseyA , FeebackJ . Does skin care frequency affect the severity of incontinence‐associated dermatitis in critically ill patients?. Nursing2014;44(12):27‐32. [sr‐incont64906] ">Conley 2014</a> used odd and even numbered days for treatment allocation. <a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a> used the last digit of medical record numbers for treatment allocation. <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a> used odd and even numbered rooms for treatment allocation. The methods used by <a href="./references#CD011627-bbs2-0007" title="ConleyP , McKinseyD , RossO , RamseyA , FeebackJ . Does skin care frequency affect the severity of incontinence‐associated dermatitis in critically ill patients?. Nursing2014;44(12):27‐32. [sr‐incont64906] ">Conley 2014</a>, <a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a> and <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a> were associated with a high risk of bias because allocation could be foreseen. </p> </section> <section id="CD011627-sec-0071"> <h4 class="title">Blinding</h4> <p>The risk of performance bias remained unclear in one trial (<a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a>). <a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a> mentioned a double‐blind design but the researchers provided no further details. Blinding of participants and personnel was not possible in 12 trials due to visual differences in appearance and use of the skin care products. </p> <p>The risk of detection bias was low in two trials (<a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a>; <a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a>), unclear in three trials (<a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a>; <a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a>; <a href="./references#CD011627-bbs2-0013" title="WangY , ZhuX , ZhouM . Comparative observation of Dermlin and Genetime used for fecal incontinence patients with perianal skin damage. Chinese Nursing Research2011;25(3C):776‐7. [sr‐incont42528] ">Wang 2011</a>), and high in the remaining eight trials. <a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a> and <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a> blinded the outcome assessment by asking experts to assess the outcomes using photographs. The <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a> trial also mentioned the removal of residual ointment using mineral oil to avoid traces of product being visible on the photographs. <a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a> mentioned a double‐blind design but provided no further details. In the remaining trials no information on the assessment procedure was given, or the assessment was not blinded. </p> </section> <section id="CD011627-sec-0072"> <h4 class="title">Incomplete outcome data</h4> <p>The risk of attrition bias due to incomplete outcome data was low in six trials (<a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>; <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a>; <a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a>; <a href="./references#CD011627-bbs2-0007" title="ConleyP , McKinseyD , RossO , RamseyA , FeebackJ . Does skin care frequency affect the severity of incontinence‐associated dermatitis in critically ill patients?. Nursing2014;44(12):27‐32. [sr‐incont64906] ">Conley 2014</a>; <a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a>; <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a>), high in two trials (<a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a>; <a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a>), and unclear in the remaining five trials (<a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a>; <a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a>; <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>; <a href="./references#CD011627-bbs2-0012" title='SchoonhovenL , vanGaalBG , TeerenstraS , AdangE , van derVleutenC , vanAchterbergT . Cost‐consequence analysis of "washing without water" for nursing home residents: a cluster randomized trial. International Journal of Nursing Studies2015;52(1):112‐20. '>Schoonhoven 2015</a>; <a href="./references#CD011627-bbs2-0013" title="WangY , ZhuX , ZhouM . Comparative observation of Dermlin and Genetime used for fecal incontinence patients with perianal skin damage. Chinese Nursing Research2011;25(3C):776‐7. [sr‐incont42528] ">Wang 2011</a>). </p> </section> <section id="CD011627-sec-0073"> <h4 class="title">Selective reporting</h4> <p>The risk of reporting bias due to selective reporting was low in eight trials (<a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>; <a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a>; <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a>; <a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a>; <a href="./references#CD011627-bbs2-0007" title="ConleyP , McKinseyD , RossO , RamseyA , FeebackJ . Does skin care frequency affect the severity of incontinence‐associated dermatitis in critically ill patients?. Nursing2014;44(12):27‐32. [sr‐incont64906] ">Conley 2014</a>; <a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a>; <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a>; <a href="./references#CD011627-bbs2-0012" title='SchoonhovenL , vanGaalBG , TeerenstraS , AdangE , van derVleutenC , vanAchterbergT . Cost‐consequence analysis of "washing without water" for nursing home residents: a cluster randomized trial. International Journal of Nursing Studies2015;52(1):112‐20. '>Schoonhoven 2015</a>), high in four trials (<a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a>; <a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a>; <a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a>; <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>), and unclear in one trial (<a href="./references#CD011627-bbs2-0013" title="WangY , ZhuX , ZhouM . Comparative observation of Dermlin and Genetime used for fecal incontinence patients with perianal skin damage. Chinese Nursing Research2011;25(3C):776‐7. [sr‐incont42528] ">Wang 2011</a>). <a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a> did not report the results in sufficient detail (e.g. no parameters of erythema readings, only proportions of participants with change in red band). <a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a> did not report the statistical methods clearly and provided only P values for some results. Furthermore, <a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a> did not give any reason for using a restricted sample size to study the time for skin breakdown. <a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a> and <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a> did not report the statistical methods and provided no P values. </p> </section> <section id="CD011627-sec-0074"> <h4 class="title">Other potential sources of bias</h4> <p>One trial used a cross‐over design without a washout period between interventions (<a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a>). Consequently, bias could have been introduced from a carry‐over effect. </p> <p>At least five trials were sponsored by industry (<a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>; <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a>; <a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a>; <a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a>; <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>). Concerning the trial of <a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>, the industrial company did the randomisation and data analysis. Concerning the trial of <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>, one of the authors was a member of the company delivering one of the trial products. In another trial the corresponding author was a member of the company delivering the trial products (<a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a>). It was not clear how the involvement of industry may have influenced the results. </p> <p>Detailed results of the risk of bias are presented in <a href="./references#CD011627-sec-0170" title="">Characteristics of included studies</a> and in <a href="#CD011627-fig-0002">Figure 2</a> and <a href="#CD011627-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD011627-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011627-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011627-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011627-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> </section> <section id="CD011627-sec-0075"> <h3 class="title" id="CD011627-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD011627-tbl-0001"><b>Summary of findings for the main comparison</b> Any topical skin care product versus another topical skin care product</a>; <a href="./full#CD011627-tbl-0002"><b>Summary of findings 2</b> Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure</a>; <a href="./full#CD011627-tbl-0003"><b>Summary of findings 3</b> Any method of application of a topical skin care product versus another method of application of the topical skin care product</a>; <a href="./full#CD011627-tbl-0004"><b>Summary of findings 4</b> Any frequency of application of a topical skin care product versus another frequency of application of the topical skin care product</a> </p> <p>In this section, we described separately the data of included trials because of variation in tested skin care products or procedures and reported outcomes. The tables in <a href="./references#CD011627-sec-0170" title="">Characteristics of included studies</a> present a more detailed description of the trials. If possible, we entered the data in Review Manager 5 to calculate risk ratios (RRs) and confidence intervals (CIs) for use in this section (<a href="./references#CD011627-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). The tables in <a href="./references#CD011627-sec-0151" title="">Data and analyses</a> present an overview of all relevant outcomes measured in the included studies and the numbers of studies measuring each outcome. We did not present effect sizes (totals and subtotals), as we did not perform any meta‐analyses. </p> <section id="CD011627-sec-0076"> <h4 class="title">1. Any topical skin care product versus another topical skin care product</h4> <p>For the same reason as described in <a href="#CD011627-sec-0066">Included studies</a>, the topical skin care products are divided into skin cleansers and leave‐on products. Leave‐on products consist of moisturisers, skin protectants/barriers, and other functions, whether combined or not, into one product. </p> <section id="CD011627-sec-0077"> <h5 class="title">Skin cleansers</h5> <p>Two trials compared a skin cleanser with soap and water (<a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a>; <a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a>). </p> <p>The <a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a> trial compared the use of the skin cleanser Clinisan with the standard use of soap and water for the prevention and treatment of incontinence‐associated dermatitis (IAD). Clinisan consists of a surfactant, emollients, dimethicone, an antibacterial agent, and perfume, and has a pH of 5.5. </p> <p>The <a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a> trial compared the use of the skin cleanser Triple Care Cleanser with the standard use of soap and water for the prevention of IAD in a cross‐over trial. </p> <section id="CD011627-sec-0078"> <h6 class="title">Primary Outcomes</h6> </section> <section id="CD011627-sec-0079"> <h6 class="title">Number of participants with incontinence‐associated dermatitis (IAD) (residual, i.e. not healed) </h6> <p>Not reported.</p> </section> <section id="CD011627-sec-0080"> <h6 class="title">Number of participants with IAD (new) (only suitable to evaluate interventions for preventing IAD) </h6> <p>The <a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a> trial (n = 87) demonstrated that less participants treated with Clinisan developed IAD during 14 days of follow‐up. In the intervention group 6/33 (18.2%) of the elderly developed IAD during the study, and in the control group 15/32 (46.9%) of the elderly developed IAD during the study. According to <a href="./references#CD011627-fig-0005" title="">Analysis 1.2</a>, this effect was significant in favour of Clinisan (RR 0.39, 95% CI 0.17 to 0.87; low quality evidence; <a href="./full#CD011627-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD011627-sec-0081"> <h6 class="title">Number of participants not satisfied with treatment</h6> <p>Not reported.</p> </section> <section id="CD011627-sec-0082"> <h6 class="title">Secondary Outcomes</h6> </section> <section id="CD011627-sec-0083"> <h6 class="title">Participants’ observations</h6> <p>Not reported.</p> </section> <section id="CD011627-sec-0084"> <h6 class="title">Quantification of symptoms (objective measures)</h6> <p>Not reported.</p> </section> <section id="CD011627-sec-0085"> <h6 class="title">Clinicians' observations</h6> <p>Not reported.</p> </section> <section id="CD011627-sec-0086"> <h6 class="title">Quality of life</h6> <p>Not reported.</p> </section> <section id="CD011627-sec-0087"> <h6 class="title">Economic data</h6> <p>The <a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a> trial (n = 10) demonstrated that for an episode of urinary incontinence, the mean difference (MD) in cleansing time was 3.87 minutes in favour of the Triple Care Cleanser (95% CI ‐4.31 to ‐3.43; P &lt; 0.001; <a href="./references#CD011627-fig-0007" title="">Analysis 1.4</a>). For an episode of both urinary and faecal incontinence, the MD in cleansing time was 9.68 minutes in favour of the Triple Care Cleanser (95% CI ‐11.71 to ‐7.65; P &lt; 0.001; <a href="./references#CD011627-fig-0007" title="">Analysis 1.4</a>). The results of this cross‐over trial were based on measurements over five treatment periods. The researchers did not provide results for the separate treatment periods. We did not find recent contact details to request more detailed information. </p> </section> <section id="CD011627-sec-0088"> <h6 class="title">Adverse effects (of the interventions)</h6> <p>Not reported.</p> </section> <section id="CD011627-sec-0089"> <h6 class="title">Other outcomes (non‐prespecified outcomes judged important when performing the review)</h6> <p>These outcomes were: IAD severity; number of participants with IAD completely healed, and number of participants with bacterial or fungal infection. </p> <p>Not reported.</p> </section> </section> <section id="CD011627-sec-0090"> <h5 class="title">Leave‐on products (moisturisers, skin protectants/barriers, combined or not)</h5> <p>Eight trials compared various leave‐on products (moisturisers, skin protectants/barriers, whether combined or not into one product) (<a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a>; <a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>; <a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a>; <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a>; <a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a>; <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a>; <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>; <a href="./references#CD011627-bbs2-0013" title="WangY , ZhuX , ZhouM . Comparative observation of Dermlin and Genetime used for fecal incontinence patients with perianal skin damage. Chinese Nursing Research2011;25(3C):776‐7. [sr‐incont42528] ">Wang 2011</a>). </p> <p>The <a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a> trial compared two different zinc oxide creams, Sudocrem and a standard zinc oxide cream. Sudocrem is claimed to have antiseptic properties and consists of 15.25% zinc oxide, 4.0% hydrous wool fat (hypoallergenic), 1.01% benzyl benzoate, 0.15% benzyl cinnamate, and 0.39% benzyl alcohol. The standard zinc oxide cream consists of 32.0% zinc oxide, 32.0% arachis oil, 0.045% calcium hydroxide, 0.5% oleic acid, and 8% wool fat. Both creams were applied liberally to groin and buttocks with each diaper/pad change for 14 days. </p> <p>The <a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a> trial compared a zinc oxide oil with the film‐forming skin product Cavilon No Sting Barrier Film for the prevention and treatment of IAD. The zinc oxide oil was applied in accordance with nursing home protocol and removed every morning and evening before re‐application, and if necessary during diaper/pad changes. The film‐forming skin product was applied every 24, 48, or 72 hours, depending on skin condition and frequency of diaper/pad change. </p> <p>The <a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a> trial compared the use of a cleansing and moisturising product followed by the application of a film‐forming skin product with the use of a washcloth (with cleansing, moisturising, and protecting properties) for the prevention of IAD. The trial products were Cavilon Skin Cleanser, Cavilon No Sting Barrier Film, and Comfort Shield Perineal Care Washcloth Dimethicone 3%. </p> <p>The <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a> trial compared Desitin and Calmoseptine, two zinc oxide based products, for the treatment of IAD. Desitin is a paste consisting of 40% zinc oxide, lanolin, petrolatum, and cod liver oil. Calmoseptine is an ointment consisting of 20% zinc oxide, menthol, chlorothymol, glycerine, lanolin, sodium bicarbonate, phenol, and thymol. In each group, one of the zinc oxide products was applied twice daily and after each incontinence episode for six days. In addition, in both groups a structured skin care procedure for the treatment of IAD was applied. The skin care procedure was provided twice daily and as required by incontinence episodes. As part of the skin care procedure, nurses removed wet or soiled diapers/pads, cleansed the skin gently with a polyhexanide wound cleansing solution using gauze pads and soft tissue and applied a thin layer of zinc oxide product prior to putting a new diaper/pad on. </p> <p>The <a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a> trial compared the combined use of a no‐rinse skin cleanser and a leave‐on product with the use of a washcloth with cleansing, moisturising, and skin protecting properties for the prevention and treatment of IAD. The researchers did not give the commercial name nor the ingredients of the products studied. </p> <p>This study was described as an abstract. The outcomes reported were not suitable for this review. The authors did not respond to our request for more information. </p> <p>The <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a> trial compared the combined use of a no‐rinse skin cleanser plus a skin cream with the use of soap and water plus a lotion for the prevention and treatment of IAD. The no‐rinse skin cleanser tested was Cavilon Antiseptic Skin Cleanser. The skin cream was Cavilon Durable Barrier Cream. The study authors did not provide the commercial name nor the ingredients of the lotion. </p> <p>The participants of the first group were cleansed with the Cavilon Antiseptic Skin Cleanser after each incontinent episode, and during the first incontinent episode per shift, a skin cream was applied. The participants of the second group were cleansed with soap (liquid or bar) and a disposable washcloth and water followed by the application of a lotion after each incontinence episode. Staff time per participant per day was measured for gathering supplies, setting supplies, cleansing participants, and application of lotion or skin cream. </p> <p>The <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a> trial compared a zinc oxide cream (Baza) with a petrolatum ointment (Peri‐Care) and a film‐forming skin product (Cavilon No Sting Barrier Film) for the treatment of IAD. The first group received Baza three times per day, and as necessary during 12 days. The second group received Peri‐Care three times a day, and as necessary. The third group received Cavilon No Sting Barrier Film with a swab applicator every 24, 48, or 72 hours. </p> <p>The <a href="./references#CD011627-bbs2-0013" title="WangY , ZhuX , ZhouM . Comparative observation of Dermlin and Genetime used for fecal incontinence patients with perianal skin damage. Chinese Nursing Research2011;25(3C):776‐7. [sr‐incont42528] ">Wang 2011</a> study compared two commercial leave‐on products, Dermlin and Genetime, for the treatment of IAD in the perianal environment. Dermlin was described as an advanced wound healing product. Genetime was described as a recombinant human epidermal growth factor. </p> <p>This study was described as a short report in Chinese. Neither the intervention nor the outcomes were clear from the English translation; we found no contact details of the study author to ask for more information. </p> <section id="CD011627-sec-0091"> <h6 class="title">Primary Outcomes</h6> </section> <section id="CD011627-sec-0092"> <h6 class="title">Number of participants with incontinence‐associated dermatitis (IAD) (residual, i.e. not healed) </h6> <p>In the <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a> trial (n = 31), 2/18 (11.1%) of the participants cared for with Cavilon Antiseptic Skin Cleanser and Cavilon Durable Barrier Cream had IAD at the end of the trial period. Of the participants cared for with soap and water plus the lotion, 4/13 (30.8%) had IAD at the end of the trial period. According to analysis in Review Manager 5 (<a href="./references#CD011627-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), this difference, in favour of Cavilon Antiseptic Skin Cleanser combined with Cavilon Durable Barrier Cream, was not significant (RR 0.36, 95% CI 0.08 to 1.68; very low quality evidence; <a href="./full#CD011627-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./references#CD011627-fig-0004" title="">Analysis 1.1</a>). </p> <p>Intention‐to‐treat analysis of the results from the <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a> trial (n=142) demonstrated that IAD did not heal in 66/73 (90.4%) participants from the Desitin group and 54/69 (78,3%) participants from the Calmoseptine group. According to analysis in Review Manager 5 (<a href="./references#CD011627-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), this difference, in favour of Calmoseptine, was not significant (RR 1.16, 95% CI 1.00 to 1.34; moderate quality evidence; <a href="./full#CD011627-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./references#CD011627-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD011627-sec-0093"> <h6 class="title">Number of participants with IAD (new) (only suitable to evaluate interventions for preventing IAD) </h6> <p>During the <a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a> trial (n = 57), 2/11 (18.2%) participants from the standard zinc oxide group and 3/16 (18.8%) participants from the Sudocrem group, who had no IAD at start of the study, developed IAD (RR 1.03, 95% CI 0.20 to 5.19; low quality evidence; <a href="./full#CD011627-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./references#CD011627-fig-0005" title="">Analysis 1.2</a>). </p> <p>The <a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a> trial (n = 64) demonstrated that the number of participants who developed IAD did not differ significantly between the group cared for with Cavilon Skin Cleanser and Cavilon No Sting Barrier Film and the group washed with the Comfort Shield Perineal Care Washcloth Dimethicone 3% (RR 0.83, 95% CI 0.35 to 1.95; low quality evidence; <a href="./full#CD011627-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./references#CD011627-fig-0005" title="">Analysis 1.2</a>). In the group cared for with Cavilon Skin Cleanser and Cavilon No Sting Barrier Film, 7/31 participants (22.6%) developed IAD. In the group washed with the Comfort Shield Perineal Care Washcloth Dimethicone 3%, 9/33 (27.3%) participants developed IAD. </p> </section> <section id="CD011627-sec-0094"> <h6 class="title">Number of participants not satisfied with treatment</h6> <p>Not reported.</p> </section> <section id="CD011627-sec-0095"> <h6 class="title">Secondary Outcomes</h6> </section> <section id="CD011627-sec-0096"> <h6 class="title">Participants’ observations</h6> <p>Not reported.</p> </section> <section id="CD011627-sec-0097"> <h6 class="title">Quantification of symptoms (objective measures)</h6> <p>One trial, the <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a> trial (n = 121), measured the change in surface affected by IAD in patients treated with Desitin (n = 65) and patients treated with Calmoseptine (n = 56). The change in surface area affected by IAD was significantly more reduced with the use of Calmoseptine (P = 0.001, MD 81.60 cm², 95% CI 36.87 to 127.33, <a href="./references#CD011627-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD011627-sec-0098"> <h6 class="title">Clinicians' observations</h6> <p>Not reported.</p> </section> <section id="CD011627-sec-0099"> <h6 class="title">Quality of life</h6> <p>Not reported.</p> </section> <section id="CD011627-sec-0100"> <h6 class="title">Economic data</h6> <p>Three trials reported on the cost of products (<a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>; <a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a>; <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>). </p> <p>The <a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a> trial (n = 39) suggested that the cost of trial products and application‐related products (price year not reported) was on average highest for zinc oxide oil (EUR 14.16, standard deviation (SD) 1.83) versus Cavilon No Sting Barrier Film (EUR 7.55, SD 8.60). Nursing time spent was also on average higher for zinc oxide oil (208.95 minutes, SD 53.84) versus Cavilon No Sting Barrier Film (161.96 minutes, SD 55.55). As a consequence, the total costs were on average higher for zinc oxide oil (EUR 102.96, SD 23.25) versus Cavilon No Sting Barrier Film (EUR 76.13, SD 25.48). The difference between groups was not measured statistically and so we cannot be sure if differences in average costs are real or not. We could not analyse these economic data in Review Manager 5 (<a href="./references#CD011627-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), because the number of participants per group was not reported, and the study authors did not respond to our request for more details. </p> <p>The <a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a> trial (n = 64) reported that the product costs per trial day (price year not reported) were significantly higher for the combined use of Cavilon Skin Cleanser and Cavilon No Sting Barrier Film (USD 6.59, n = 31) compared to the use of Comfort Shield Perineal Care Washcloth Dimethicone 3% (USD 2.67, n = 33) (P = 0.006). Because no SDs or other statistics were reported, we were unable to undertake analysis in Review Manager 5 (<a href="./references#CD011627-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>The <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a> trial (n = 40) suggested that Peri‐Care (n = 8) was on average less expensive than Baza (n = 8) in terms of daily cost of product use (Peri‐Care USD 0.8 versus Baza USD 1.2) (price year 1995). Baza was less expensive than Cavilon No Sting Barrier Film if Cavilon No Sting Barrier Film was applied every 24 (n = 8) or 48 hours (n = 8) (Baza USD 1.2 versus Cavilon No Sting Barrier Film USD 2.3 or USD 1.1). Baza was on average more expensive than Cavilon No Sting Barrier Film, if the latter was applied every 72 hours (n = 8) (Baza USD 1.2 versus Cavilon No Sting Barrier Film USD 0.8). Peri‐Care was on average less expensive than Cavilon No Sting Barrier Film if the latter was applied every 24 or 48 hours (Peri‐Care USD 0.8 versus Cavilon No Sting Barrier Film USD 2.3 or USD 1.1). Peri‐Care costs on average the same as Cavilon No Sting Barrier Film if the latter was applied every 72 hours (USD 0.8). No levels of significance were provided and as a consequence it is unclear whether any difference in average costs are real. Due to the limited reporting of statistical data, we were unable to perform analysis in Review Manager 5 (<a href="./references#CD011627-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We found no recent contact details of the study authors to ask for more information. </p> <p>One trial, the <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a> trial (n = 31), reported on staff time. Staff time was on average shorter for the combined use of Cavilon Antiseptic Skin Cleanser plus Cavilon Durable Barrier Cream than for the combined use of soap and water plus the lotion. In the first group (n = 18), staff time was 41 minutes per day for an average of seven incontinence episodes per day. The mean duration of cleansing was five minutes, and for the application of Cavilon Durable Barrier Cream, two minutes. In the second group (n = 13), staff time was 120 minutes per day for an average of eight incontinence episodes per day. The mean duration of cleansing was 13 minutes, and for the application of the lotion, two minutes. No levels of significance were provided and as a consequence it is unclear whether any difference in average staff time are real. It was not possible to undertake analysis in Review Manager 5 because SDs were not reported (<a href="./references#CD011627-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). The study authors did not respond on our request for more details. </p> <p>One trial, the <a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a> trial (n = 39), reported on incremental cost‐effectiveness, reported as the incremental cost per 1 point improvement in skin condition. The incremental cost per 1 point improvement was EUR 98.06 for zinc oxide oil, and EUR 28.36 for Cavilon No Sting Barrier Film (price year not reported). No estimate of the imprecision around this estimate of incremental cost‐effectiveness was reported. Following guidance from Campbell and Cochrane Economics Methods Group, it is not appropriate to consider meta‐analysis of such data. Rather consideration should focus on what issues might determine such results. </p> </section> <section id="CD011627-sec-0101"> <h6 class="title">Adverse effects (of the interventions)</h6> <p>The <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a> trial reported that no adverse effects occurred during the study while using Desitin and Calmoseptine. </p> </section> <section id="CD011627-sec-0102"> <h6 class="title">Other outcomes (non‐prespecified outcomes judged important when performing the review)</h6> <p>These outcomes were: IAD severity; number of participants with IAD completely healed, and number of participants with bacterial or fungal infection. </p> <section id="CD011627-sec-0103"> <p><b>IAD severity</b></p> <p>Four trials reported on IAD severity (<a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a>; <a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>; <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>; <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a>). </p> <p>The <a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a> trial (n = 57) demonstrated a reduction in IAD severity in 92.3% of the participants from the Sudocrem group (n = 29) and 37.5% of the participants from the standard zinc oxide group (n = 28) after seven days. A reduction in IAD severity was identified in 84.6% of the participants from the Sudocrem group and 50.0% of the participants from the standard zinc oxide group after 14 days. The researchers mentioned a significantly greater improvement of IAD severity in favour of Sudocrem at both time points (P &lt; 0.01). Because only percentages were provided, it was not possible to undertake an analysis in Review Manager 5for the outcome 'IAD severity' (<a href="./references#CD011627-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We found no recent contact details of the study authors to ask for more information. </p> <p>The <a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a> trial (n = 39) demonstrated an improvement in IAD severity in participants treated with zinc oxide oil as in participants treated with Cavilon No Sting Barrier Film, with a significantly greater improvement in the group treated with Cavilon No Sting Barrier Film (P = 0.04). Because only a P value was reported, it was not possible to undertake an analysis in Review Manager 5 (<a href="./references#CD011627-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>The <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a> trial (n = 40) demonstrated that the IAD severity improved significantly in participants treated with Peri‐Care (n = 8), Baza (n = 8) or Cavilon No Sting Barrier Film (n = 24). No statistics were provided. None of the groups showed a significantly greater improvement in IAD severity than the other. Due to the limited reporting of statistical data, we were unable to perform analysis in Review Manager 5 (<a href="./references#CD011627-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We found no recent contact details of the study authors to ask for more information. </p> <p>The <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a> trial (n = 31) demonstrated that the severity of IAD did not significantly differ between the group cared for with Cavilon Antiseptic Skin Cleanser and Cavilon Durable Barrier Cream (mean score 0.28/4, SD 0.83, n = 18) and the group cared for with soap and water plus the lotion (mean score 0.77/4, SD 1.30, n = 13). The MD was ‐0.49 (95% CI ‐1.29 to 0.31; <a href="./references#CD011627-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD011627-sec-0104"> <p><b>Number of participants with IAD completely healed</b></p> <p>One trial, the <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a> trial (n = 142), reported on the number of participants with IAD completely healed during a follow‐up period of six days. Based on the intention‐to‐treat analysis, 15/69 (21.7%) participants from the Calmoseptine group and 7/73 (9.6%) participants from the Desitin group completely healed during the study. According to analysis in Review Manager 5 (<a href="./references#CD011627-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), the difference, in favour of Calmoseptine, was not significant (RR 0.44, 95% CI 0.19 to 1.02; <a href="./references#CD011627-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD011627-sec-0105"> <p><b>Number of participants with bacterial or fungal infection</b></p> <p>One trial, the <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a> trial (n = 142), reported on the number of participants with fungal infections as a secondary outcome. During this trial, 4/142 (2.8%) participants were withdrawn because of fungal infections in the IAD area. </p> </section> </section> </section> </section> <section id="CD011627-sec-0106"> <h4 class="title">2. Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure </h4> <p>Two trials compared a skin care procedure (method or frequency of application) versus soap and water (<a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a>; <a href="./references#CD011627-bbs2-0012" title='SchoonhovenL , vanGaalBG , TeerenstraS , AdangE , van derVleutenC , vanAchterbergT . Cost‐consequence analysis of "washing without water" for nursing home residents: a cluster randomized trial. International Journal of Nursing Studies2015;52(1):112‐20. '>Schoonhoven 2015</a>). </p> <p>The <a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a> trial compared a structured skin care procedure using a washcloth with cleansing, moisturising, and skin protecting properties with the standard use of soap and water. The trial washcloth was the Comfort Shield Perineal Care Washcloth Dimethicone 3%. </p> <p>The intervention group was washed daily with the Comfort Shield Perineal Care Washcloth at routine perineal skin hygiene times, and after each diaper/pad change. No towel rubbing was allowed. In case of an extremely soiled skin, a soft washcloth and lukewarm water to remove soiling and a soft towel were used to dry the skin. The control group was washed with a soft washcloth, soap (pH 6.5 to 7.5) and water at routine perineal skin hygiene times, and after each diaper/pad change. </p> <p>The <a href="./references#CD011627-bbs2-0012" title='SchoonhovenL , vanGaalBG , TeerenstraS , AdangE , van derVleutenC , vanAchterbergT . Cost‐consequence analysis of "washing without water" for nursing home residents: a cluster randomized trial. International Journal of Nursing Studies2015;52(1):112‐20. '>Schoonhoven 2015</a> trial compared the use of a washcloth impregnated with a lotion with soap and water for the prevention and treatment of skin abnormalities and skin lesions. The trial washcloths were the Wet Wash Gloves from Abena. </p> <p>The intervention group was washed daily in bed with the Wet Wash Gloves which were heated in the microwave before use. No towel rubbing was allowed. The control group was washed daily using tap water and soap (different types), wash gloves, and towels. </p> <p>The report of this trial provides results on skin abnormalities (e.g. erythema, erosions, discolorations of the wound bed) and significant skin lesions (non‐intact skin). These results, however, were not specific for IAD, but included any kind of skin abnormalities and lesions over the whole body. </p> <section id="CD011627-sec-0107"> <h5 class="title">Primary Outcomes</h5> </section> <section id="CD011627-sec-0108"> <h5 class="title">Number of participants with incontinence‐associated dermatitis (IAD) (residual, i.e. not healed) </h5> <p>The <a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a> trial (n = 141) demonstrated that, after 120 days, significantly fewer participants washed with the Comfort Shield Perineal Care Washcloth (n = 73) had IAD versus the group washed with soap and water (n = 68). After adjusting for clustering effect, 7.9% participants washed with the washcloth had IAD versus 25.9% of the participants washed with soap and water (RR 0.31, 95% CI 0.12 to 0.79; moderate quality evidence; <a href="./full#CD011627-tbl-0002">summary of findings Table 2</a>; <a href="./references#CD011627-fig-0010" title="">Analysis 2.1</a>). </p> </section> <section id="CD011627-sec-0109"> <h5 class="title">Number of participants with IAD (new) (only suitable to evaluate interventions for preventing IAD) </h5> <p>Not reported.</p> </section> <section id="CD011627-sec-0110"> <h5 class="title">Number of participants not satisfied with treatment</h5> <p>Not reported.</p> </section> <section id="CD011627-sec-0111"> <h5 class="title">Secondary Outcomes</h5> </section> <section id="CD011627-sec-0112"> <h5 class="title">Participants’ observations</h5> <p>Not reported.</p> </section> <section id="CD011627-sec-0113"> <h5 class="title">Quantification of symptoms (objective measures)</h5> <p>Not reported.</p> </section> <section id="CD011627-sec-0114"> <h5 class="title">Clinicians' observations</h5> <p>Not reported.</p> </section> <section id="CD011627-sec-0115"> <h5 class="title">Quality of life</h5> <p>Not reported.</p> </section> <section id="CD011627-sec-0116"> <h5 class="title">Economic data</h5> <p>Not reported.</p> </section> <section id="CD011627-sec-0117"> <h5 class="title">Adverse effects (of the interventions)</h5> <p>The <a href="./references#CD011627-bbs2-0012" title='SchoonhovenL , vanGaalBG , TeerenstraS , AdangE , van derVleutenC , vanAchterbergT . Cost‐consequence analysis of "washing without water" for nursing home residents: a cluster randomized trial. International Journal of Nursing Studies2015;52(1):112‐20. '>Schoonhoven 2015</a> trial reported the absence of any Suspected Unexpected Serious Adverse Reaction occurring while comparing the use of a washcloth impregnated with a lotion with soap and water. </p> </section> <section id="CD011627-sec-0118"> <h5 class="title">Other outcomes (non‐prespecified outcomes judged important when performing the review)</h5> <p>These outcomes were: IAD severity; number of participants with IAD completely healed, and number of participants with bacterial or fungal infection. </p> <section id="CD011627-sec-0119"> <h6 class="title">IAD severity</h6> <p>One trial, the <a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a> trial (n = 141), reported on IAD severity. At the end of this trial, the IAD severity was significantly less in the group washed with the Comfort Shield Perineal Care Washcloth (n = 73) versus the group washed with soap and water (n = 68) (MD ‐2.50, 95% CI ‐3.19 to ‐1.81, <a href="./references#CD011627-fig-0011" title="">Analysis 2.2</a>). </p> </section> <section id="CD011627-sec-0120"> <h6 class="title">Number of participants with IAD completely healed</h6> <p>Not reported.</p> </section> <section id="CD011627-sec-0121"> <h6 class="title">Number of participants with bacterial or fungal infection</h6> <p>The <a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a> trial also reported on the number of participants developing any bacterial or fungal infection. During this trial, no participants developed any bacterial or fungal infection. </p> </section> </section> </section> <section id="CD011627-sec-0122"> <h4 class="title">3. Any method of application of a topical skin care product versus another method of application of the topical skin care product </h4> <p>No suitable trials were found.</p> </section> <section id="CD011627-sec-0123"> <h4 class="title">4. Any frequency of application of a topical skin care product versus another frequency of application of the topical skin care product </h4> <p>Two trials compared different frequencies of application of topical skin care products (<a href="./references#CD011627-bbs2-0007" title="ConleyP , McKinseyD , RossO , RamseyA , FeebackJ . Does skin care frequency affect the severity of incontinence‐associated dermatitis in critically ill patients?. Nursing2014;44(12):27‐32. [sr‐incont64906] ">Conley 2014</a>; <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>) </p> <p>The <a href="./references#CD011627-bbs2-0007" title="ConleyP , McKinseyD , RossO , RamseyA , FeebackJ . Does skin care frequency affect the severity of incontinence‐associated dermatitis in critically ill patients?. Nursing2014;44(12):27‐32. [sr‐incont64906] ">Conley 2014</a> trial tested a structured skin care procedure, including the application of a skin cleanser and a leave‐on product, for the prevention and treatment of IAD. The skin cleanser and the leave‐on product were applied every six hours or every 12 hours. The skin care procedure consisted of gentle cleansing of the skin with the skin cleanser containing Aloe vera mixed with water and a cleansing lotion followed by patting the skin dry. If no erythema was observed, a leave‐on product with silicone was applied. If erythema was present, a leave‐on product with zinc oxide and menthol was applied. </p> <p>The <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a> trial compared three frequencies of the application of a film‐forming skin product (Cavilon No Sting Barrier Film: every 24, 48, or 72 hours. </p> <section id="CD011627-sec-0124"> <h5 class="title">Primary Outcomes</h5> </section> <section id="CD011627-sec-0125"> <h5 class="title">Number of participants with incontinence‐associated dermatitis (IAD) (residual, i.e. not healed) </h5> <p>The <a href="./references#CD011627-bbs2-0007" title="ConleyP , McKinseyD , RossO , RamseyA , FeebackJ . Does skin care frequency affect the severity of incontinence‐associated dermatitis in critically ill patients?. Nursing2014;44(12):27‐32. [sr‐incont64906] ">Conley 2014</a> trial (n = 99) identified no significant difference in the number of participants with IAD when performing the skin care procedure every six hours (56.4%) versus every 12 hours (60.0%) (P = 0.718). We were unable to perform any analysis in Review Manager 5 because the study authors only provided percentages for the outcome of interest and no statistics on missing data (<a href="./references#CD011627-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). The study authors did not reply to our request for more details. </p> </section> <section id="CD011627-sec-0126"> <h5 class="title">Number of participants with IAD (new) (only suitable to evaluate interventions for preventing IAD) </h5> <p>Not reported.</p> </section> <section id="CD011627-sec-0127"> <h5 class="title">Number of participants not satisfied with treatment</h5> <p>Not reported.</p> </section> <section id="CD011627-sec-0128"> <h5 class="title">Secondary Outcomes</h5> </section> <section id="CD011627-sec-0129"> <h5 class="title">Participants’ observations</h5> <p>Not reported.</p> </section> <section id="CD011627-sec-0130"> <h5 class="title">Quantification of symptoms (objective measures)</h5> <p>Not reported.</p> </section> <section id="CD011627-sec-0131"> <h5 class="title">Clinicians' observations</h5> <p>Not reported.</p> </section> <section id="CD011627-sec-0132"> <h5 class="title">Quality of life</h5> <p>Not reported</p> </section> <section id="CD011627-sec-0133"> <h5 class="title">Economic data</h5> <p>One trial, the <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a> trial (n = 40), reported on the cost of products (Price year 1995). This trial demonstrated that the application of Cavilon No Sting Barrier Film every 72 hours (n = 8) was the least expensive (USD 0.8), followed by the application every 48 hours (n = 8) (USD 1.1) and the application every 24 hours (n = 8) (USD 2.3). Because no SDs were reported, we were unable to undertake an analysis in Review Manager 5 (<a href="./references#CD011627-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD011627-sec-0134"> <h5 class="title">Adverse effects (of the interventions)</h5> <p>Not reported.</p> </section> <section id="CD011627-sec-0135"> <h5 class="title">Other outcomes (non‐prespecified outcomes judged important when performing the review)</h5> <p>These outcomes were: IAD severity; number of participants with IAD completely healed, and number of participants with bacterial or fungal infection. </p> <section id="CD011627-sec-0136"> <h6 class="title">IAD severity</h6> <p>One trial, the <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a> trial (n = 40), reported on the IAD severity. This trial demonstrated that the IAD severity improved significantly in participants treated with Cavilon No Sting Barrier Film every 24 hours (n = 8), every 48 hours (n = 8) or every 72 hours (n = 8). No statistics were mentioned. None of the groups showed a significantly greater improvement in IAD severity than the other. Due to the limited reporting of statistical data, we were unable to perform any analysis in Review Manager 5 (<a href="./references#CD011627-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We found no recent contact details of the study authors to ask for more information. </p> </section> <section id="CD011627-sec-0137"> <h6 class="title">Number of participants with IAD completely healed</h6> <p>Not reported.</p> </section> <section id="CD011627-sec-0138"> <h6 class="title">Number of participants with bacterial or fungal infection</h6> <p>Not reported.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011627-sec-0139" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011627-sec-0139"></div> <p>The aim of this review was to assess and compare the effectiveness of various products and procedures to prevent and treat incontinence‐associated dermatitis (IAD) in adults. In this context, the review focused on topical skin care products, structured skin care procedures, application methods for topical skin care products, and frequency of application of topical skin care products. </p> <section id="CD011627-sec-0140"> <h3 class="title" id="CD011627-sec-0140">Summary of main results</h3> <section id="CD011627-sec-0141"> <h4 class="title">Primary outcomes</h4> <p>Four trials assessed the effectiveness of topical skin care products (skin cleansers and leave‐on products) against the outcome 'number of participants with IAD (residual/new)' (<a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a>; <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a>; <a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a>; <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a>). Two of these trials (<a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a>; <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a>) tested a combined use of skin care products in each trial group (for example, a skin cleanser and a leave‐on product). One trial compared the use of a skin cleanser with soap and water (<a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a>). Another trial assessed whether a structured skin care procedure could reduce the same outcome (as above) in comparison with soap and water (<a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a>). </p> <p>Based on the included trials, we found low quality evidence for the effectiveness of a skin cleanser (Clinisan) compared with soap and water. We found evidence of moderate quality for the effectiveness of a structured skin care procedure (using a washcloth with cleansing, moisturising, and protecting properties; Comfort Shield Perineal Care Washcloth Dimethicone 3%) compared with soap and water. No differences were found between topical skin care products (skin cleansers and leave‐on products) in reducing the number of participants with IAD. However, it should be noticed that the sample size of the latter trials was rather small (&lt; 100 participants), except for the <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a> trial (n = 142) . </p> </section> <section id="CD011627-sec-0142"> <h4 class="title">Secondary outcomes</h4> <p>One trial assessed the outcomes 'size of the skin lesion' (surface affected by IAD) and 'number of participants completely healed' (<a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a>). The researchers compared two different zinc oxide based leave‐on products (Desitin and Calmoseptine) and identified a significant difference in favour of Calmoseptine for both outcomes. However, the two products differed in the amount of zinc oxide being applied (20% in Calmoseptine, 40% in Desitin) and the presence of other active ingredients (such as menthol in Calmoseptine and lanolin, petrolatum, and cod liver oil in Desitin). Consequently, it is not clear which amount of zinc oxide is optimal or which ingredients are pivotal for the treatment of IAD. </p> <p>Low quality evidence was found for economic data ('cost of product', 'staff time', 'incremental cost‐effectiveness'), based on a few small studies. </p> <p>Two trials compared the costs for daily use of various leave‐on products (zinc oxide based products, petrolatum ointment) with those of a film‐forming skin product (also a leave‐on product) (<a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>; <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>). The methods used for economic analysis varied across these trials. It should also be mentioned that the zinc oxide products and the petrolatum ointment were applied more frequently than the film‐forming skin product (at least twice daily versus every 24, 48, or 72 hours). The findings from the <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a> study, which seem to be outdated, indicated that the film‐forming skin product Cavilon No Sting Barrier Film was more expensive on average if applied on a daily base. However, if this film‐forming skin product could be applied every 72 hours, then it would be less expensive on average than the zinc oxide cream, Baza and the petrolatum ointment, Peri‐Care (<a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>). Furthermore, if the costs for application‐related products (gloves, spatula, gauze) were included, then the film‐forming skin product mentioned above, applied according to participants' needs, would be less expensive on average than the zinc oxide oil (<a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>). The lack of statistical comparison hover means that no conclusion can be drawn about differences in cost. </p> <p>One trial reported that the cost for the daily use of a washcloth with cleansing, moisturising and protecting properties (Comfort Shield Perineal Care Washcloth Dimethicone 3%) was significantly lower than the use of two separate leave‐on products (Cavilon Skin Cleanser and Cavilon No Sting Barrier Film) (<a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a>). </p> <p>Staff time was assessed in two small trials comparing soap and water with a skin cleanser (<a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a>; <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a>). The findings from both trials indicated that staff time can be reduced when using a no‐rinse skin cleanser (including Triple Care Cleanser and Cavilon Antiseptic Skin Cleanser). This could be expected as washing with a no‐rinse skin cleanser does not need the filling and emptying of a water basin and the drying of the participant with a towel. However, no statistical comparisons were reported and conclusions remain tentative. </p> <p>The incremental cost‐effectiveness was calculated for the comparison of zinc oxide oil with a film‐forming skin protectant (<a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>). When using the film‐forming skin protectant Cavilon No Sting Barrier Film, the application frequency, application‐related product costs and staff time were on average lower than when using zinc oxide oil. In addition, IAD severity was also significantly lower. No estimate of the imprecision around this estimate was provided and no guidance was provided as to how interpret the incremental cost‐effectiveness result. The trial team however concluded that the total costs (for products and staff time) per point improvement in IAD severity were in favour of the film‐forming skin protectant Cavilon No Sting Barrier Film compared with zinc oxide oil. </p> <p>Three trials reported results on the outcome 'IAD severity' when comparing various leave‐on products (zinc oxide products, petrolatum ointment, film‐forming skin protectant). In one small trial (n = 34), IAD severity improved more when using the film‐forming skin protectant Cavilon No Sting Barrier Film compared with zinc oxide oil (<a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>). However, another similar trial, found no significant difference comparing the same film‐forming skin protectant with the zinc oxide cream, Baza (<a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>). The latter trial included only 16 participants. A last trial found more improvement in terms of reduced skin redness when using Sudocrem compared to a standard zinc oxide cream (<a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a>). Because of other differences in composition of these two products (such as amount of zinc oxide applied), it was not clear whether the ingredients responsible for the antiseptic properties of Sudocrem determined the outcome. As described above, the trials of <a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a>, <a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a> and <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a> compared different leave‐on products with each other. The overall findings of these trials suggested that IAD severity improved for all leave‐on products. </p> <p>One trial analysed the improvement in IAD severity when comparing a structured skin care procedure (washcloth with cleansing, moisturising, and protecting properties) with soap and water (<a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a>). In this trial, only residents washed with the washcloth (Comfort Shield Perineal Care Washcloth Dimethicone 3%) showed a significant improvement in IAD severity. </p> </section> </section> <section id="CD011627-sec-0143"> <h3 class="title" id="CD011627-sec-0143">Overall completeness and applicability of evidence</h3> <p>This review included 13 (quasi‐)RCTs in a qualitative synthesis. The trials provided data for only two of the three proposed primary outcomes (‘number of participants with IAD residual (i.e. not healed)’ and ‘number of participants with IAD (new)’) and three of the seven proposed secondary outcomes (‘quantification of symptoms’, ‘economic data’ and ‘other outcomes’). We did not find data on four of seven participant‐important outcomes: ‘number of participants not satisfied with treatment’, ‘number of participants with pain due to IAD’, ‘number of participants with pain due to skin care products or procedure’ and ‘adverse reaction due to skin care product or procedure’. </p> <p>Although we included only 13 trials, this review contains results on a wide range of topical skin care products (n = 15) and procedures (n = 3). We studied the three subgroups of topical skin care products (see <a href="#CD011627-sec-0046">Types of interventions</a>): no‐rinse skin cleansers, moisturisers, and skin protectants, either as separate products or combined into one product. We also studies structured skin care procedures. Nevertheless, the variation in products and procedures did not allow us to pool data. </p> <p>Almost half of the trials (n = 6) included participants with IAD as well as without IAD at the start of the trial. We did not perform a subgroup analysis. Consequently, we could not identify if the tested skin care products and procedures performed as well in the prevention as the treatment of IAD. </p> <p>We found two ongoing studies (see <a href="./references#CD011627-sec-0173" title="">Characteristics of ongoing studies</a>). The <a href="./references#CD011627-bbs2-0039" title="NCT02570139 . Multi‐center, randomized trial comparing the efficacy of 3M™ Cavilon™ Advanced Barrier Film for the treatment of incontinence‐associated dermatitis to a commercially available moisture barrier. https://clinicaltrials.gov/show/NCT02570139 (accessed 29 September 2016)2015. ">NCT02570139 2015</a> trial compares the use of two film forming skin protectants, Cavilon Advanced High Endurance Skin Protectant and ConvaTec Sensi‐Care Protective Barrier (n = 102). The outcomes measured in this trial are IAD severity, IAD healing, pain due to IAD, and prevention of IAD development. The <a href="./references#CD011627-bbs2-0040" title="NCT02690753 . A turn and positioning system and standardized incontinence care combined with tailored repositioning versus a standard repositioning protocol for pressure ulcer prevention: a multicenter prospective randomized controlled clinical trial and health economical analysis in a hospital setting. https://clinicaltrials.gov/show/NCT02690753 (accessed 29 September 2016)2016. ">NCT02690753 2016</a> trial compares a washcloth with cleansing, moisturising and skin protecting properties (Comfort Shield Barrier Cream Cloths) with standard care (n = 226) . The outcomes measured include number of participants with IAD (new), and comfort and tolerance of the participants. The reports of these studies will be analysed for the next update of this review. </p> </section> <section id="CD011627-sec-0144"> <h3 class="title" id="CD011627-sec-0144">Quality of the evidence</h3> <p>A quantitative meta‐analysis was not appropriate. We were unable to pool the results from the different trials due to heterogeneity in participant population, skin care products, skin care procedure, outcomes, and measurement tools. </p> <p>Almost all trials showed at least two sources of bias. Selective reporting of trial results was a less common source of bias and was present in four trials (<a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a>; <a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a>; <a href="./references#CD011627-bbs2-0009" title="DieterL , DrolshagenC , BlumK . Cost‐effective, quality care for the patient with incontinence. Thirty‐eigth Annual Meeting of Wound Ostomy and Continence Nurse Society; 2006 June 24‐28; Minneapolis. Minneapolis (MN): Wound Ostomy and Continence Nurse Society, 2006. [sr‐incont27316] ">Dieter 2006</a>; <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>), and unclear in one trial (<a href="./references#CD011627-bbs2-0013" title="WangY , ZhuX , ZhouM . Comparative observation of Dermlin and Genetime used for fecal incontinence patients with perianal skin damage. Chinese Nursing Research2011;25(3C):776‐7. [sr‐incont42528] ">Wang 2011</a>). Lack of blinding was the most common source of bias. Blinding of participants and personnel was not possible in all but one trial due to visual differences in the skin care products (<a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a>). In only two trials (<a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a>; <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a>), the outcome assessors were blinded by using photographs. Another possible source of bias was funding. At least five trials were funded by industry (<a href="./references#CD011627-bbs2-0002" title="Baatenburg de JongH , AdmiraalH . Comparing cost per use of 3M Cavilon No Sting Barrier Film with zinc oxide oil in incontinent patients. Journal of Wound Care2004;13(9):398‐400. [sr‐incont19444] ">Baatenburg de Jong 2004</a>; <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a>; <a href="./references#CD011627-bbs2-0006" title="ByersPH , RyanPA , ReganMB , ShieldsA , CartaSG . Effects of incontinence care cleansing regimens on skin integrity. Journal of Wound, Ostomy, and Continence Nursing1995;22(4):187‐92. [sr‐incont2967] ">Byers 1995</a>; <a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a>; <a href="./references#CD011627-bbs2-0010" title="KennedyKL , LutzJ . Comparison of the efficacy and cost‐effectiveness of three skin protectants in the management of incontinence dermatitis. 1996 European Conference on Advances in Wound Management; 1996 Oct 4; Amsterdam. Amsterdam, 1996. [sr‐incont67959] ">Kennedy 1996</a>). The overall risk of bias in the included studies was high. </p> <p>We could only perform a GRADE assessment of the quality of evidence for two of the primary outcomes of this review, ‘number of participants with IAD (new)’ and ‘number of participants with IAD (residual, i.e. not healed)’; with six single studies. This was due to a lack of statistical data (standard deviations, frequencies) necessary to calculate risk ratios or mean differences. The results from the GRADE assessment showed low to very low quality of evidence for four trials, based on the risk of bias described above (<a href="./references#CD011627-bbs2-0001" title="AnthonyD , BarnesE , Malone‐LeeJ , PluckR . A clinical study of Sudocrem in the management of dermatitis due to the physical stress of incontinence in a geriatric population. Journal of Advanced Nursing1987;12(5):599‐603. [sr‐incont519] ">Anthony 1987</a>; <a href="./references#CD011627-bbs2-0004" title="BrunnerM , DroegemuellerC , RiversS , DeuserWE . Prevention of incontinence‐related skin breakdown for acute and critical care patients: comparison of two products. Urologic Nursing2012;32(4):214‐9. [sr‐incont45816] ">Brunner 2012</a>; <a href="./references#CD011627-bbs2-0008" title="CooperP , GrayD . Comparison of two skin care regimes for incontinence. British Journal of Nursing2001;10(6 Suppl):S6‐S10. [sr‐incont14649] ">Cooper 2001</a>; <a href="./references#CD011627-bbs2-0011" title="Lewis‐ByersK , ThayerD . An evaluation of two incontinence skin care protocols in a long‐term care setting. Ostomy Wound Management2002;48(12):44‐51. [sr‐incont15851] ">Lewis‐Byers 2002</a>). Furthermore, the imprecision of the point estimates was serious (large confidence intervals) as a consequence of small sample sizes. Only the <a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a>, and the <a href="./references#CD011627-bbs2-0005" title="BuckleyB , DofitasR , BaltazarW , QuiambaoP , RazorB . Topical zinc oxide based creams in a structured care regimen for the treatment of incontinence associated dermatitis in hospitalized adults and older children: A randomized, controlled trial (Abstract number 321). Neurourology and Urodynamics2014;33(6):760‐1. [sr‐incont64413] RazorB , BuckleyB , QuiambaoP , DofitasR , BaltazarW . Incontinence‐associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide‐based ointment. World Council of Enterostomal Therapists Journal2014;34(4):13‐23. ">Buckley 2014</a> studies showed moderate quality evidence. The <a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a> trial was the only trial which proved (post hoc) an adequate sample size to detect real differences (statistical power). </p> <p>As a conclusion, the quality of evidence for the prevention and management of IAD was very low to moderate. All data should be interpreted with caution. </p> </section> <section id="CD011627-sec-0145"> <h3 class="title" id="CD011627-sec-0145">Potential biases in the review process</h3> <p>We performed a rigorous literature search to prevent missing relevant trials. We searched the Cochrane Incontinence Group Specialised Trial Register, major databases, reference lists, and conference proceedings. In addition, we contacted specialists in the field and all authors of the included studies. Furthermore, all review authors are experts in the field, and performed multiple literature reviews on healthcare subjects, and more specifically on the prevention and treatment of IAD in adults. Finally, we only identified three supplementary trials via reference lists. As a consequence, we believe the possibility of missing any relevant trial was low. </p> <p>The Cochrane Review protocol was written out and followed in detail. All steps in the review process were performed by at least two (independently working) researchers. In addition, the interpretation of the findings was done by all review authors, working in different countries around the globe. This minimised the risk for errors, inaccuracies, and influences of individual interest. Furthermore, experience was brought together. </p> <p>The strict inclusion criteria limited the number of studies available for inclusion. Many trials were not performed in adults, not randomised, did not test topical skin care products or did not meet the proposed outcomes. Whilst the inclusion criteria limited the list of included studies, the studies with the strongest set‐up were used to draw conclusions. </p> </section> <section id="CD011627-sec-0146"> <h3 class="title" id="CD011627-sec-0146">Agreements and disagreements with other studies or reviews</h3> <p>This review confirms the conclusions of two other systematic reviews. <a href="./references#CD011627-bbs2-0043" title="BeeckmanD , SchoonhovenL , VerhaegheS , HeynemanA , DefloorT . Prevention and treatment of incontinence‐associated dermatitis: Literature review. Journal of Advanced Nursing2009;65(6):1141‐54. ">Beeckman 2009</a> identified limited evidence for the effectiveness of various interventions for the prevention and treatment of IAD in adults. Furthermore, as in our Cochrane Review, soap and water performed poorly in the prevention and treatment of IAD. Similarly, the <a href="./references#CD011627-bbs2-0049" title="CorcoranE , WoodwardS . Incontinence‐associated dermatitis in the elderly: treatment options. British Journal of Nursing2013;22(8):450‐7. ">Corcoran 2013</a> study, which focused on trials testing skin protectants, could not recommend any skin protectant over another due to a lack of evidence. Both reviews identified the same weaknesses in trial design: absence of power calculations in advance, small sample sizes, no blinded assessments, and short trial periods. Based on the findings of our review and the <a href="./references#CD011627-bbs2-0003" title="BeeckmanD , VerhaegheS , DefloorT , SchoonhovenL , VanderweeK . A 3‐in‐1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence‐associated dermatitis: a randomized, controlled clinical trial. Journal of Wound, Ostomy, and Continence Nursing2011;38(6):627‐34. [sr‐incont42976] ">Beeckman 2011</a> and <a href="./references#CD011627-bbs2-0049" title="CorcoranE , WoodwardS . Incontinence‐associated dermatitis in the elderly: treatment options. British Journal of Nursing2013;22(8):450‐7. ">Corcoran 2013</a> reviews, it is clear that the available evidence on topical skin care products and procedures for prevention and management of IAD in adults is limited. More research to draw conclusions needs to be done. </p> <p>The trials included in our review studied various topical skin care products (skin cleansers and leave‐on products) for the prevention and treatment of IAD. Some commercial leave‐on products seem to perform better than others, but we could not identify which ingredients were responsible for this difference in effectiveness. Recently Kottner and Beeckman published an overview of knowledge and recommendations concerning IAD and pressure ulcers in geriatric patients (<a href="./references#CD011627-bbs2-0061" title="KottnerJ , BeeckmanD . Incontinence‐associated dermatitis and pressure ulcers in geriatric patients. Giornale Italiano di Dermatologia e Venereologia2015;150(6):717‐29. ">Kottner 2015</a>). These authors combined research findings with expert opinion. Kottner and Beeckman agreed with the existence of various skin care products concerning IAD and the lack of evidence on differences in benefits between products. In addition, they described that the performance of leave‐on products not only depends on individual ingredients but especially on the combination of ingredients and the overall formulation. Furthermore, in accordance with our finding that most trials made no explicit distinction between the prevention and treatment of IAD, Kottner and Beeckman described the absence of a technology to promote skin barrier recovery after maceration in the elderly (<a href="./references#CD011627-bbs2-0061" title="KottnerJ , BeeckmanD . Incontinence‐associated dermatitis and pressure ulcers in geriatric patients. Giornale Italiano di Dermatologia e Venereologia2015;150(6):717‐29. ">Kottner 2015</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011627-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/urn:x-wiley:14651858:media:CD011627:CD011627-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_t/tCD011627-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram." data-id="CD011627-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#CD011627-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011627-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/urn:x-wiley:14651858:media:CD011627:CD011627-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_t/tCD011627-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011627-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#CD011627-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011627-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/urn:x-wiley:14651858:media:CD011627:CD011627-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_t/tCD011627-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011627-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#CD011627-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011627-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/urn:x-wiley:14651858:media:CD011627:CD011627-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_t/tCD011627-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any topical skin care product versus another topical skin care product, Outcome 1 Number of participants with IAD (residual, i.e. not healed)." data-id="CD011627-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Any topical skin care product versus another topical skin care product, Outcome 1 Number of participants with IAD (residual, i.e. not healed). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/references#CD011627-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011627-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/urn:x-wiley:14651858:media:CD011627:CD011627-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_t/tCD011627-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any topical skin care product versus another topical skin care product, Outcome 2 Number of participants with IAD (new)." data-id="CD011627-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Any topical skin care product versus another topical skin care product, Outcome 2 Number of participants with IAD (new). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/references#CD011627-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011627-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/urn:x-wiley:14651858:media:CD011627:CD011627-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_t/tCD011627-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any topical skin care product versus another topical skin care product, Outcome 3 Surface affected by IAD (measurement of size of lesion)." data-id="CD011627-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Any topical skin care product versus another topical skin care product, Outcome 3 Surface affected by IAD (measurement of size of lesion). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/references#CD011627-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011627-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/urn:x-wiley:14651858:media:CD011627:CD011627-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_t/tCD011627-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any topical skin care product versus another topical skin care product, Outcome 4 Staff time." data-id="CD011627-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Any topical skin care product versus another topical skin care product, Outcome 4 Staff time. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/references#CD011627-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011627-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/urn:x-wiley:14651858:media:CD011627:CD011627-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_t/tCD011627-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any topical skin care product versus another topical skin care product, Outcome 5 Number of participants with IAD completely healed." data-id="CD011627-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Any topical skin care product versus another topical skin care product, Outcome 5 Number of participants with IAD completely healed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/references#CD011627-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011627-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/urn:x-wiley:14651858:media:CD011627:CD011627-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_t/tCD011627-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Any topical skin care product versus another topical skin care product, Outcome 6 IAD severity." data-id="CD011627-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Any topical skin care product versus another topical skin care product, Outcome 6 IAD severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/references#CD011627-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011627-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/urn:x-wiley:14651858:media:CD011627:CD011627-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_t/tCD011627-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure, Outcome 1 Number of participants with IAD (residual, i.e. not healed)." data-id="CD011627-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure, Outcome 1 Number of participants with IAD (residual, i.e. not healed). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/references#CD011627-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011627-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/urn:x-wiley:14651858:media:CD011627:CD011627-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_t/tCD011627-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure, Outcome 2 IAD Severity." data-id="CD011627-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure, Outcome 2 IAD Severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/references#CD011627-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/media/CDSR/CD011627/image_n/nCD011627-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011627-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Any topical skin care product versus another topical skin care product</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Any topical skin care product versus another topical skin care product</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with incontinence<br/> <b>Setting:</b> hospitals and nursing homes<br/> <b>Intervention:</b> any topical skin care product<br/> <b>Comparison:</b> another topical skin care product </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with skin care product B</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with skin care product A</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (residual, i.e. not healed)</b> </p> <p>(1) No‐rinse skin cleanser and skin cream (A) versus soap and water and lotion (B)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.36<br/> (0.08 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on one small study.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1.000<br/> (25 to 517) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (residual, i.e. not healed)</b> </p> <p>(2) Desitin (A) versus Calmoseptine (B)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.16</p> <p>(1.00 to 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>142</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Basd on one study and sponsored by industry.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>783 per 1.000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>908 per 1.000<br/> (783 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (new)</b> </p> <p>(1) Skin cleanser (A) versus soap and water (B)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.39<br/> (0.17 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on one small study and sponsored by industry.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>469 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1.000<br/> (80 to 408) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (new)</b> </p> <p>(2) Sudocrem (A) versus zinc oxide cream (B)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (0.20 to 5.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on one small study.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1.000<br/> (36 to 944) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (new)</b> </p> <p>(3) No‐rinse skin cleanser/moisturiser and a film‐forming skin product (A) versus cleansing/moisturising/skin protecting washcloth (B) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/> (0.35 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>64<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on one small study. Corresponding author was member of the company who delivered the study products. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>226 per 1.000<br/> (95 to 532) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants not satisfied with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to IAD</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to skin care product or procedure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse reaction due to the skin care product or procedure, e.g. skin irritation, rash, itching, allergic</b> <br/> <b>reaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incremental cost‐effectiveness</b> </p> <p>Zinc oxide oil (A) versus film‐forming skin product (B)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> VERY LOW </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One small study reported data on this outcome. The results on cost‐effectiveness were on average in favour of the film‐forming skin product. Due to limited reporting of statistical data, it is unclear whether these differences in cost‐effectiveness are real. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IAD</b> : incontinence‐associated dermatitis; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Any topical skin care product versus another topical skin care product</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#CD011627-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011627-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with incontinence<br/> <b>Setting:</b> nursing homes<br/> <b>Intervention:</b> any skin care procedure (method or frequency of application)<br/> <b>Comparison:</b> any unstructured skin care procedure </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any unstructured skin care procedure (B)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any skin care procedure (method or frequency of application) (A)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (residual, i.e. not healed)</b> </p> <p>(1) Washcloth with cleansing, moisturising, and protecting properties (A) versus water and pH neutral soap (B) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.31<br/> (0.12 to 0.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Based on one study.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>259 per 1.000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1.000<br/> (31 to 204) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with IAD (new)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants not satisfied with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to IAD</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to skin care product or procedure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse reaction due to the skin care product or procedure, e.g. skin irritation, rash, itching, allergic</b> <br/> <b>reaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incremental cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IAD</b> : incontinence‐associated dermatitis; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#CD011627-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011627-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Any method of application of a topical skin care product versus another method of application of the topical skin care product</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Any method of application of a topical skin care product versus another</b> <br/> <b>method of application of the topical skin care product</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with incontinence<br/> <b>Setting:</b> <br/> <b>Intervention:</b> any method of application of a topical skin care product<br/> <b>Comparison:</b> any other method of application of the topical skin care product </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any unstructured skin care procedure (B)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any skin care procedure (method or frequency of application) (A)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (residual, i.e. not healed)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with IAD (new)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants not satisfied with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to IAD</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to skin care product or procedure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse reaction due to the skin care product or procedure, e.g. skin irritation, rash, itching, allergic<br/> reaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incremental cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IAD</b> : incontinence‐associated dermatitis; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Any method of application of a topical skin care product versus another method of application of the topical skin care product</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#CD011627-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011627-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Any frequency of application of a topical skin care product versus another frequency of application of the topical skin care product</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Any frequency of application of a topical skin care product versus another<br/> frequency of application of the topical skin care product</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with incontinence<br/> <b>Setting:</b> <br/> <b>Intervention:</b> any frequency of application of a topical skin care product<br/> <b>Comparison:</b> any other frequency of application of the topical skin care product </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any unstructured skin care procedure (B)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with any skin care procedure (method or frequency of application) (A)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants with IAD (residual, i.e. not healed)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with IAD (new)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants not satisfied with treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to IAD</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants with pain due to skin care product or procedure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse reaction due to the skin care product or procedure, e.g. skin irritation, rash, itching, allergic<br/> reaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Incremental cost‐effectiveness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data for this outcome were reported in the eligible studies.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IAD</b> : incontinence‐associated dermatitis; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Any frequency of application of a topical skin care product versus another frequency of application of the topical skin care product</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/full#CD011627-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011627-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Any topical skin care product versus another topical skin care product</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants with IAD (residual, i.e. not healed) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No‐rinse skin cleanser and skin cream (A) versus soap and water and lotion (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Desitin (A) versus Calmoseptine (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants with IAD (new) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Skin cleanser (A) versus soap and water (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Sudocrem (A) versus zinc oxide cream (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 No‐rinse skin cleanser/moisturiser and film‐forming skin product (A) versus cleansing/moisturising/skin protecting washcloth (B) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Surface affected by IAD (measurement of size of lesion) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Desitin (A) versus Calmoseptine (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Staff time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Skin cleanser/moisturiser (A) versus soap and water (B) (urine)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Skin cleanser/moisturiser (A) versus soap and water (B) (urine and stool)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 No‐rinse skin cleanser and a skin cream (A) versus soap and water and a lotion (B) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants with IAD completely healed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Desitin (A) versus Calmoseptine (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 IAD severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Sudocrem (A) versus zinc oxide cream (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 No‐rinse skin cleanser and skin cream (A) versus soap and water and lotion (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Zinc oxide cream (A) versus petrolatum ointment (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Zinc oxide cream (A) versus film‐forming skin product (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Petrolatum ointment (A) versus film‐forming skin product (B)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Any topical skin care product versus another topical skin care product</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/references#CD011627-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011627-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants with IAD (residual, i.e. not healed) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Washcloth with cleansing, moisturising, and protecting properties (A) versus water and pH neutral soap (B) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 IAD Severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Washcloth with cleansing, moisturising, and protecting properties (A) versus water and pH neutral soap (B) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011627.pub2/references#CD011627-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011627.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011627-note-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011627-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011627-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD011627-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD011627-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011627-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011627\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011627\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011627\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011627\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011627\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011627.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011627.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011627.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011627.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011627.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715228541"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011627.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715228545"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011627.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d81f56b90f446',t:'MTc0MDcxNTIyOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 